

# The Asian National Stop TB Partnership Forum 2016



Date: 14 and 15, March, 2016

Venue:

United Nations University, Shibuya, Tokyo (14, March)  
Research Institute of Tuberculosis, JATA, Kiyose, Tokyo (15, March)

Stop TB Partnership Japan  
Japanese Council of Women's Anti-TB Associations  
Japan Anti-Tuberculosis Association

## Table of Contents

---

|   | page#  |
|---|--------|
| Table of Contents   | 1      |
| Report of the Asian National Stop TB Partnership Forum 2016                       | 3      |
| Appendix 1    List of Participants  | 7      |
| Appendix 2    Introduction of Japanese Women's Anti-TB Association                | 9      |
| Appendix 3    Challenges of Current TB Problem to Today's Asia                    | 13     |
| Appendix 4    Country Presentations   | 19     |
| WHO Epidemiological data  |        |
| Cambodia Anti-TB Association  | 25     |
| Forum Stop TB Partnership Indonesia   | 30     |
| Stop TB Partnership Korea   | 35     |
| Myanmar Maternal and Child Welfare Association                                    | 39     |
| Japan-Nepal Health & TB Research Association                                      | 47     |
| RIT/ JATA Philippines, Inc.   | 52     |
| Chang-Hua TB Care Association Taiwan  | 60     |
| TB/HIV Research Foundation Thailand   | 65     |
| Appendix 5    Group Discussion 1    Challenges of NGO to End TB and role of women | 71     |
| Appendix 6    Group Discussion 2    Fundraising for the community activities      | 75     |
| Appendix 7    Tokyo Statement on Community Engagement in End TB Strategy          | 79     |
| <br>報 告        アジア・ナショナル・ストップ結核パートナーシップフォーラム 2016                                 | <br>85 |
| 東京宣言    「結核早期根絶戦略」におけるコミュニティの参加   | 89     |
| 写真集<br>(Photographs)  | 93     |



# Report of the Asian National Stop TB Partnership Forum 2016

The Stop TB Partnership Japan

The Asia Stop TB Partnership Forum 2016 was held in Tokyo, Japan, on 14 and 15 March, 2016. Following is the summary report of the presentations and discussions in the Forum meeting.

## Main theme

Community people's roles in End TB Strategy in Asia

## Purposes of the Forum

To bring together the delegates of Stop TB Partnerships (or similar non-governmental organizations, e.g., Anti-Tuberculosis Association)) of Asian countries / territories, and to discuss over the current non-governmental efforts against tuberculosis, their perspectives into the near future, with special emphasis on the roles of women, and possibility of its strengthening, and collaboration between partnerships across borders, aiming at the earlier achievement of End TB Target in Asia.

## Expected Outcomes

1. To enhance people's awareness of the importance of their ownership for and commitment with the tuberculosis control activities
2. To promote the effective collaboration between governmental and non-governmental sectors in the fight against tuberculosis
3. To clarify the problems and challenges of tuberculosis control of each country / area and to develop action plan addressing them with non-governmental efforts
4. To deepen the understanding of the potentiality of women's efforts in the community activities
5. To advance cooperation between partners of different countries / territories

Date 14 and 15, March, 2016

## Venue

United Nations University, Shibuya, Tokyo (14, March)

Research Institute of Tuberculosis, JATA, Kiyose, Tokyo (15, March)



## Participants

A total of 18 participants representing non-governmental organizations of 8 countries / territories were invited (see Appendix 1). In addition, there were 26 observers from various governmental and non-governmental institutions / groups, including Ministry of Foreign Affairs and JICA.

## Agenda and Results

### 1. Opening and Introduction of Participants and Staff

Chair: Dr. Toru Mori (Executive Board Representative, Stop TB Partnership Japan)

### 2. Lecture 1: 14 March (United Nations University)

Thema: Women's Anti-TB Activities in Japan

Lecturer: Ms. Takeko Yamashita

Secretary General, Japanese Council of women's Anti-TB Associations

Abstract (see Appendix 2)

### 3. Lecture 2: 14 March (United Nations University)

Thema: Challenges of Current TB Problem to Today's Asia

Lecturer: Dr. Nobuyuki Nishikiori

Coordinator, Stop TB and Leprosy Elimination, WPRO, WHO

Abstract (see Appendix 3)

### 4. Courtesy visit and exchange with Japanese Council of Women's Anti-TB Associations members, 14 March (Hotel New Otani, the venue of Annual National Assembly of the Council)

### 5. Presentation and discussion of activities of Country / Territory partnerships: 14 and 15 March (Research Institute of TB)

Chair: Dr. Kosuke Okada (Director, International Cooperation, Japan Anti-TB Association)

(See Appendix 4)

### 6. Group Discussion 1: 15 March (Research Institute of TB)

Thema : Challenges to NGO's activities and women's roles

Moderator: Dr. Nobukatsu Ishikawa (Director, Research Institute of TB, JATA)

(See Appendix 5)

7. Group discussion 2 : 15 March (Research Institute of TB)

Thema: Fund raising plan in the community activities

Moderator: Ms. Jintana Ngamvitayapong-Yanai (TB-HIV Research Foundation,  
Thailand)

(See Appendix 6)

8. Adoption of the Forum Statement: 15 March (Research Institute of TB)

Chair: Dr. Toru Mori (Executive Board Representative, Stop TB Partnership  
Japan)

(See Appendix 7; Tokyo Statement of Asian National Stop TB Partnership Forum  
2017)

9. Reception: 15 March (Research Institute of TB)

Special Guest: Mr. Kintaro Shibuya, Mayor of Kiyose City



## Appendix 1

### List of Participants

| Country /Territory | Name                         | Affiliation  |
|--------------------|------------------------------|--|
| Cambodia           | Khloeung Phally              | Deputy Director of National Center for Tuberculosis and Leprosy Control (CENAT)                        |
|                    | Monyrath Chry                | Program manager of Cambodia Anti-Tuberculosis Association(CATA)  |
|                    | Chharvy Ringsey KEO          | Cambodia Anti-Tuberculosis Association(CATA)   |
| Indonesia          | Mariani Reksoprodjo          | Head Quarter/ Executive Secretary of Forum Stop TB Partnership Indonesia                               |
|                    | Fitriani Manan               | Board member of Stop TB Partnership Cimahi City  |
| Korea              | Seungjoon Chang              | Executive Director of Stop TB Partnership Korea , Korean National Tuberculosis Association(KNTA)       |
|                    | Kanghee Kim                  | Chief of Stop TB Partnership Korea, Korean National Tuberculosis Association(KNTA)                     |
|                    | Hong Jo Choi                 | Korean Institute of Tuberculosis(KIT)  |
| Myanmar            | Tha Zin Nwe                  | Chairperson of Myanmar Maternal Welfare Association(MMWA)  |
|                    | Ei Ei Chaw                   | State TB Officer of National Tuberculosis Program, Kachin State, Myitkyinar                            |
| Nepal              | Ram Sharan Gopali            | Country Representative of Japan-Nepal Health & TB Research Association RIT(JANTRA) / JATA Nepal Office |
|                    | Jamuna Panthi                | Board member of JANTRA   |
| Philippines        | Aurora G. Querri             | Deputy Executive Director of RIT/JATA, Philippines, Inc.(RJPI)   |
|                    | Leonardo G. Parungo Jr       | Administrative Officer of RIT/JATA, Philippines, Inc.(RJPI)  |
| Taiwan             | Chih-Yun Lin                 | Research Assistant of Tuberculosis MDR Department, Chang-Hua Hospital/Anti-TB Association(TATA)        |
|                    | Wei-Wen Chen                 | Chang-Hua Hospital MDR TB Department/Anti-TB Association(TATA)   |
| Thailand           | Luangjina Sarmwai            | Secretary of THRF, Member of the Chiang Rai Volunteer Ladies against TB                                |
|                    | Jintana Ngamvitayapong-Yanai | President of TB/HIV Research Foundation (THRF)   |



## Abstract of Lecture 2

### Beautiful Health: Introduction of Japanese Women's Anti-TB Association

- The 30-year history of the Japanese Women's Fight against TB –

**Origin** The Association (Officially: Council of Japanese Women's Anti-TB Associations) dates back to the foundation of the Women's Committee of Nagano City in July 1950, when there was an opportunity for the leaders of the women's association of Nagano City to have an audience with Princess Chichibu, who was then the President of the Japan Anti-TB Association (JATA). The Princess inspired them to dedicate themselves to TB control.

The anti-TB movement of Nagano was further stimulated by a tuberculosis (TB) outbreak that occurred in September of the same year. The TB epidemic broke out in a primary school of a town of Nagano Prefecture. This incident ignited the women's activity to eliminate TB from their community and homes.

This movement developed into an organization covering the entire prefecture of Nagano by 1957, the Nagano council of Women's Anti-TB Association, as the very first organization of this kind in Japan.

**Development** The movement to eliminate TB through the wisdom and efforts of housewives has been further expanded. It became increasingly active and has been materialized as the All Japan Housewives' Convention for Healthy Family, and the Leaders' Seminar of Women's Anti-TB Association. A poster for Anti-TB Week adopted the slogan, "The Housewife is a key person in TB prevention."

In 1975, the National Women's Anti-TB Association was established. It was approved as a corporate juridical person in 1977 and has become the largest women's health organization in Japan. In 1996, the Association celebrated its 20th anniversary. The Association has come a long way, extending activities all over Japan, responding to the changing time and situation, as the largest women's health movement in Japan.

During these several decades, deaths due to TB that used to be feared as a non-curable illness, have decreased drastically. This may be ascribed to the efforts of related organizations and authorities, as well as the activities of the women's Association. To disseminate ideas of TB prevention and its motivation, the Association

continues its activities at the grass-roots level, as an organization for protecting people's health.

**Liaison with JATA** The National Assembly of TB Prevention of JATA has been held every year since 1949. This assembly discusses what to do in the non-governmental anti-TB activities and how to address their current challenges. The Women's Association supports this assembly and is actively involved in planning and implementing this event. The National Assembly is also the venue for the Women's Association to convene for the Annual Convention Meeting and the Annual Board Meeting to discuss the future agenda of the Association.

**National Seminar** The National Seminar of the Women's Ant-TB Association was launched in 1997. The seminar provides the opportunity for learning about TB and other related public health issues and also for exchanging information among members. Having acquired new knowledge and information in the course, the participants became more aware of the importance of community activities for communication with the people.

**Local Leader's Seminar** Such achievements as these could be reflected in the local leaders' seminar in a total of seven areas of Japan, as bases for local associations' guidelines, which in turn will be a source of their community activities.

**Advocacy in Community** The Association actively targets the communication and advocacy activities on TB prevention not only for the family but for the society in general. Public information media such as leaflets and brochures have been developed in order to disseminate the ideas and knowledge of TB prevention to children and adults. Regarding actions toward local governments, the Association members pay courtesy visits to governors/mayors to appeal for strengthening the public TB control services. Such grass-roots activities of women are significant for disseminating knowledge of TB and for increasing the awareness of the people, and can also help to fill any gaps in governmental services.

**Fund Raising** The Association has been involved in fund raising as a means of talking about TB prevention directly to the people. In cooperation with the JATA branch of prefectures, the Association runs the double-barred cross-seal campaign for fund-raising all over Japan during the TB Prevention Week, i.e., during the 4th week of September. Indeed, the women's activities provide important support for the double-barred-cross seal campaign. The double-barred-cross seal campaign was

initiated in the beginning of the 20th century in Denmark as the Christmas Seal Campaign and now has now become a symbol of TB prevention worldwide. In Japan, JATA has devoted itself to this program since 1952 with the support of the government to promote TB control with the support and cooperation of the general public and in partnership with foreign countries.

The funds raised by this campaign are an important source for supporting JATA's activities. The Women's Association plays the most vital role in this campaign, contributing about 30% of the total funds raised. The funds thus raised by this campaign are spent for the various activities of JATA for the sake of people's health.

**International Cooperation: Study Tour** An important area of activity supported by the fund from the campaign is international cooperation. JATA's international cooperation includes its unique grass-roots project that is a long-lasting program with promoting DOTS as its core. The study-tour is a group tour for the members of the Association who are involved in fund raising to become more aware of the TB situation of developing countries. The tour is a good opportunity to understand the significance of the seal campaign vividly and is a source of energy for future activity. The program of the study tour was launched in 1994, and since then, we have visited TB project sites, such as Nepal and Myanmar, and we visited Cambodia in 2006.

The Association's cooperation has been extended to the national anti-TB associations of developing countries that are faced with various difficulties in TB control.

TB control takes a long time to bear fruit and needs a solid organizational basis with financial assistance. In this context, the seal campaign can be a great help for people of developing countries, and it proved surely useful.

**Publication** "Health Circle" is the official journal of the Association intended to transmit the newest knowledge of tuberculosis and public health in general to the Association members, and to strengthen the partnership among members. The journal was first published in 1977 and is now issued three times every year (40,000 copies each). This communication paper is distributed not only to the Association members, but also widely to related organizations throughout Japan, such as JATA branches; the Ministry of Health, Labour and Welfare; and Prefectural and Local governments and Public Health Centers to broadly report the activities of the Women's Association.

**The Way Forward** Thirty years have passed since the foundation of the



Association as a corporate juridical person. Its contribution to TB control in Japan has been indispensable. However, TB still has not been eliminated. The emergence of multidrug-resistant TB, the upsurge of TB among elderly persons and urban youngsters -- -- -- all these issues are complicating the TB problem, and we should address them properly. Also, we need to address the increasing life-style related illnesses and newly emerging respiratory diseases.

Globally, over 1.5 million people lose their lives due to TB every year. In order to contribute to the worldwide fight against TB, the Association joined the Stop TB Partnership Japan. The Women's Anti-TB Association is steadily endeavoring to achieve its purpose. Its current slogan is: health management throughout the life of the people through promoting control of TB and life-style related illnesses so that people can enjoy a happy and healthy life. This slogan was adopted in the 58th National Anti-TB Assembly. Thus, the women are determined to lead the national movement for the people to maintain their own health.

## Appendix 3

### Appendix 3

Presentation of Dr. Nishikiori



### Surpassing MDGs and other targets in the Western Pacific Region



World Health Organization Regional Office for the Western Pacific

### "Challenges of Current TB Problem to Today's Asia"

#### Regional Framework for Action on Implementation of the End TB Strategy in the Western Pacific Region


The Asian National Stop TB Partnership Forum,  
14–15 March 2016, Tokyo, Japan

Dr Nobu Nishikiori, Coordinator  
Stop TB and Leprosy Elimination  
World Health Organization  
Regional Office for the Western Pacific



World Health Organization Regional Office for the Western Pacific

### TB burden in the Western Pacific Region




|                                       |  |
|---------------------------------------|--|
| Estimate number of TB (all forms)     | <b>1.6 million</b><br>(85 per 100 000) |
| Estimated number of deaths due to TB* | <b>88 000</b><br>(4.8 per 100 000)     |
| Multidrug-resistant TB                | <b>71 000</b>                          |
| HIV-associated TB                     | <b>31 000</b>                          |

All estimates are for 2014.  
Source: Global TB Report 2015 (WHO)  
\* Excluding death due to TB-HIV co-infection



World Health Organization Regional Office for the Western Pacific

### MDG6 TB target achieved




But huge burden of deaths and suffering remains.  
9.6 million people fell ill with TB in 2014, and there were 1.5 million deaths




### Challenges

1. Many patients **unreached**
2. **Insensitive** diagnostics
3. Vulnerable and **high-risk** groups
4. Only a small fraction of **MDR-TB** patients diagnosed, yet treatment capacity insufficient
5. Limitations in **health systems**



World Health Organization Regional Office for the Western Pacific

## Increasing difficulty in TB diagnosis




(Data from The Second National TB Prevalence Survey, Cambodia, 2011)




World Health Organization Regional Office for the Western Pacific

## MDR-TB diagnosis, enrolment vs estimated in the Western Pacific Region



World Health Organization Regional Office for the Western Pacific


## Need for more sensitive diagnostics



World Health Organization Regional Office for the Western Pacific

## TB drugs in the private sector market


- **Growing evidence on a huge private sector drug market**
  - Public procurement sufficient for all notified TB case (Blue bar and line)
  - Private sector drug sales are almost equivalent to the notified TB cases (Red bar)
  - Five times more drugs for initial treatment relative to drugs for continuous phase
- **Reflecting:**
  - A weak notification system
  - Incomplete treatment in the private sector
  - Unnecessary patient costs




World Health Organization Regional Office for the Western Pacific

## Financial hardship of TB patients and families ~ losing a half of annual income ~

- TB patients in low-and middle-income countries face expense equivalent to more than 50% of their annual income.
- A half of the costs are incurred before TB treatment
- Patients often have to resort to coping mechanisms that may be irreversible:
  - up to 75% of TB patients must take out a loan;
  - up to 50% sell household items; and
  - up to 66% rely on financial support from relatives.
- Addressing catastrophic patient cost is prerequisite for further advancing TB control



World Health Organization Regional Office for the Western Pacific



## The End TB Strategy

### Draft Regional Framework for Action



World Health Organization Regional Office for the Western Pacific

## END TB Vision, goal, targets, milestones



**Vision:**  
A world free of TB  
Zero TB deaths,  
Zero TB disease, and Zero  
TB suffering

**Goal:**  
End the Global TB  
epidemic

|  | MILESTONES |      | TARGETS   |             |
|--|------------|------|-----------|-------------|
|  | 2020       | 2025 | SDG* 2030 | END TB 2035 |
| Reduction in number of TB deaths (compared with 2015 est.)   | 30%        | 70%  | 90%       | 95%         |
| Reduction in TB incidence rate (compared with 2015 est.)     | 20%        | 50%  | 80%       | 90%         |
| TB-related burden during comprehensive health due to TB (Hq) | 0%         | 0%   | 0%        | 0%          |

World Health Organization

SDG 3: Good Health and Well-being

END TB

## Global commitment to End TB

Moving from halting TB to ending TB by 2030

SDG 3.3 “End the epidemics of AIDS, tuberculosis, malaria and neglected tropical Diseases”




World Health Organization


SDG 3: Good Health and Well-being

END TB

## Projected acceleration of TB incidence decline to target levels



## Health development model in the context of Sustainable Development



## END TB The End TB Strategy: 3 pillars and 4 principles



## Regional Framework for Action on Implementation of the End TB Strategy


### Purpose

- Facilitate the adaptation and implementation of the End TB Strategy

### Structure and contents


- Follow the same three-pillar structure with 7 components
- Each component composed of:
  - Strategy
  - Regional situation
  - Proposed actions
- Region specific issues:
  - High risk groups, opportunities for social protection, urban TB control, co-morbidity management

Endorsed by Member States in 66<sup>th</sup> RCM in Oct 2015



World Health Organization Regional Office for the Western Pacific

## Paradigm shift in TB control



World Health Organization Regional Office for the Western Pacific

## Regional Framework for Action

### Pillar 1: Integrated, people-centred care and prevention

- Treatment and care for all TB patients
  - MDR-TB
  - TB among children
  - High-risk populations (enhancing contact investigation)
  - TB/HIV
  - Co-morbidities
- TB laboratory networks
- Latent TB infection and BCG vaccination

### Pillar 3: Research

- Enhancing TB research capacity

### Pillar 2: Bold policies and supportive systems


- Governance and stewardship
  - NSP and TB control financing
  - UHC policy and TB control
  - Drug regulatory systems
  - Disease notification and surveillance systems
- Engagement of public and private providers
- Addressing social determinants and social protection



World Health Organization Regional Office for the Western Pacific

## Key areas elaborated

- People centered care → Principle
  - WPRO/SEARO 2007 Policy Document
- Co-morbidity management
  - Link with ageing societies
- TB care financing in the context of UHC
  - WPRO's policy framework on sustainable financing for priority health programmes
- Social protection floor
  - ILO Recommendation R202
- Social determinants
  - HiAP & Urban TB control



World Health Organization Regional Office for the Western Pacific


## Attributes highlighted and elaborated

- Paradigm shift in TB control
- Apply health system strategies and concepts
- Covering the whole epidemiological spectrum
- People-centred care




World Health Organization Regional Office for the Western Pacific

## Changes in TB incidence between 1994-2013



World Health Organization Regional Office for the Western Pacific

## Evolution of the TB control components along with an epidemiological spectrum



\* Only selected components are shown for the illustrative purpose.


World Health Organization Regional Office for the Western Pacific

## A vision beyond DOT: People-centred health care


- Health care that is **organized around patients**, families and communities
  - Responding **holistic needs** of patients, rather than the needs of programmes or systems
    - Medical, psychological, social, and financial
    - Strong service coordination
- Action domains
- Informed and empowered patients, families and communities
  - Competent and responsive health workers
  - Efficient and humane health care organizations
  - Supportive health systems

World Health Organization Regional Office for the Western Pacific

## Three tiers of actions



World Health Organization Regional Office for the Western Pacific



World Health Organization Regional Office for the Western Pacific

## TB control as a global public good for health

- Public goods—e.g. safe drinking water, clean air, etc.
- TB control has been regarded as a classic example of “a public good for health”
  - TB control in one setting will benefit everybody
  - Collective (global/regional) TB control is impacted by the level of control achieved in the worst national TB program (the weak link characteristics)
- This principle is a key for continued advocacy for sustainable public financing as well as cross-country collaboration**


Smith R., Beaglehole R., Woodward D., Drager N. (ed.) Global Public Goods for Health: health economics and public health perspectives.

World Health Organization Regional Office for the Western Pacific

## Summary

- Substantial achievement in TB control globally
- Remaining and emerging challenges
  - TB among high-risk and vulnerable populations
  - Scaling up response to drug-resistant TB
  - Building sustainable TB control system while contributing to the overall health system strengthening efforts
- The End TB Strategy and its Regional Framework opened up new era of TB control
  - From a vertical programme to “an essential health system competency”
  - People-centeredness as a core principle
  - All countries to be aligned and cooperate for regional/global TB control

World Health Organization Regional Office for the Western Pacific



Regional Framework for Action  
on Implementation of the End TB  
Strategy in the Western Pacific,  
2016–2020

Thank you!



World Health Organization Regional Office for the Western Pacific



## Appendix 4

### Country Presentations

#### 1. Epidemiological Data (Cited from WHO: Global TB Report 2015, and others)

## Cambodia

Population 2014

15 million

| Estimates of TB burden * 2014 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 8.9 (6.3–12)       | 58 (41–78)                    |
| Mortality (HIV+TB only)       | 0.82 (0.63–1)      | 5.3 (4.1–6.7)                 |
| Prevalence (includes HIV+TB)  | 100 (87–120)       | 668 (565–780)                 |
| Incidence (includes HIV+TB)   | 60 (54–66)         | 390 (353–428)                 |
| Incidence (HIV+TB only)       | 1.8 (1.6–2)        | 12 (10–13)                    |

|                               |            |
|-------------------------------|------------|
| Case detection, all forms (%) | 72 (66–80) |
|-------------------------------|------------|

| Estimates of MDR-TB burden * 2014              | New           | Retreatment  |
|--|---------------|--------------|
| % of TB cases with MDR-TB                      | 1.4 (0.7–2.5) | 11 (4–22)    |
| MDR-TB cases among notified pulmonary TB cases | 330 (160–590) | 200 (73–400) |

| TB case notifications 2014             | New ** | Relapse |
|--|--------|---------|
| Pulmonary, bacteriologically confirmed | 12 168 | 445     |
| Pulmonary, clinically diagnosed        | 11 286 | 709     |
| Extrapulmonary                         | 18 310 | 141     |

|  |               |
|--|---------------|
| <b>Total new and relapse</b>           | <b>43 059</b> |
| Previously treated, excluding relapses | 679           |
| <b>Total cases notified</b>            | <b>43 738</b> |

Among 43 059 new and relapse cases:  
12 050 (28%) cases aged under 15 years; male:female ratio: 1.2

| Reported cases of RR-/MDR-TB 2014        | New      | Retreatment | Total ** |
|--|----------|-------------|----------|
| Cases tested for RR-/MDR-TB              | 646 (5%) | 1 329 (67%) | 1 975    |
| Laboratory-confirmed RR-/MDR-TB cases    |          |             | 110      |
| Patients started on MDR-TB treatment *** |          |             | 110      |

| TB/HIV 2014   | Number | (%)  |
|---|--------|------|
| TB patients with known HIV status                                   | 35 635 | (81) |
| HIV-positive TB patients  | 953    | (3)  |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 938    | (98) |
| HIV-positive TB patients on antiretroviral therapy (ART)            | 938    | (98) |
| HIV-positive people screened for TB                                 | 3 504  |      |
| HIV-positive people provided with IPT                               | 901    |      |

| Treatment success rate and cohort size                          | (%)  | Cohort |
|---|------|--------|
| New and relapse cases registered in 2013                        | (93) | 35 536 |
| Previously treated cases, excluding relapse, registered in 2013 | (90) | 1 701  |
| HIV-positive TB cases, all types, registered in 2013            |      |        |
| RR-/MDR-TB cases started on second-line treatment in 2012       | (79) | 110    |
| XDR-TB cases started on second-line treatment in 2012           |      |        |

| Laboratories 2014                                      |     |
|--|-----|
| Smear (per 100 000 population)                         | 1.4 |
| Culture (per 5 million population)                     | 1.3 |
| Drug susceptibility testing (per 5 million population) | 1.0 |
| Sites performing Xpert MTB/RIF                         | 17  |
| Is second-line drug susceptibility testing available?  | No  |

| Financing TB control 2015                    |     |
|--|-----|
| National TB programme budget (US\$ millions) | 31  |
| % Funded domestically                        | 12% |
| % Funded internationally                     | 47% |
| % Unfunded                                   | 42% |


\* Ranges represent uncertainty intervals

\*\* Includes cases with unknown previous TB treatment history

\*\*\* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB


### Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population)




— Prevalence

(Rate per 100 000 population per year)




— Notified (new and relapse) — Incidence  
— Incidence (HIV+TB only)

(Number of patients)




— HIV-positive TB patients  
— on CPT — on ART

Treatment success rate (%)



— New — Retreatment  
— New and relapse — Retreatment, excluding relapse  
— HIV-positive — RR-/MDR-TB — XDR-TB

Total budget (US\$ millions)



— Funded domestically — Funded internationally  
— Unfunded



# Indonesia

Population 2014

254 million

| Estimates of TB burden * 2014 | Number (thousands)  | Rate (per 100 000 population) |
|-------------------------------|---------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 100 (66–150)        | 41 (26–59)                    |
| Mortality (HIV+TB only)       | 22 (13–32)          | 8.5 (5.2–13)                  |
| Prevalence (includes HIV+TB)  | 1 600 (1 300–2 000) | 647 (513–797)                 |
| Incidence (includes HIV+TB)   | 1 000 (700–1 400)   | 399 (274–546)                 |
| Incidence (HIV+TB only)       | 63 (41–90)          | 25 (16–36)                    |

|                               |            |
|-------------------------------|------------|
| Case detection, all forms (%) | 32 (23–46) |
|-------------------------------|------------|

| Estimates of MDR-TB burden * 2014              | New                 | Retreatment       |
|--|---------------------|-------------------|
| % of TB cases with MDR-TB                      | 1.9 (1.4–2.5)       | 12 (8.1–17)       |
| MDR-TB cases among notified pulmonary TB cases | 5 600 (4 200–7 400) | 1 100 (770–1 600) |

| TB case notifications 2014             | New **  | Relapse |
|--|---------|---------|
| Pulmonary, bacteriologically confirmed | 193 321 | 6 449   |
| Pulmonary, clinically diagnosed        | 101 991 | 1 391   |
| Extrapulmonary                         | 19 653  | 1       |

**Total new and relapse** 322 806

Previously treated, excluding relapses 1 733

**Total cases notified** 324 539

Among 322 806 new and relapse cases:  
23 170 (7%) cases aged under 15 years; male:female ratio: 1.4

| Reported cases of RR-/MDR-TB 2014        | New         | Retreatment | Total ** |
|--|-------------|-------------|----------|
| Cases tested for RR-/MDR-TB              | 1 058 (<1%) | 8 445 (88%) | 9 503    |
| Laboratory-confirmed RR-/MDR-TB cases    |             |             | 1 812    |
| Patients started on MDR-TB treatment *** |             |             | 1 284    |

| TB/HIV 2014   | Number | (%)  |
|---|--------|------|
| TB patients with known HIV status                                   | 15 074 | (5)  |
| HIV-positive TB patients  | 2 355  | (16) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 963    | (41) |
| HIV-positive TB patients on antiretroviral therapy (ART)            | 624    | (26) |
| HIV-positive people screened for TB                                 |        |      |
| HIV-positive people provided with IPT                               |        |      |

| Treatment success rate and cohort size                          | (%)  | Cohort  |
|---|------|---------|
| New and relapse cases registered in 2013                        | (88) | 325 582 |
| Previously treated cases, excluding relapse, registered in 2013 | (64) | 1 521   |
| HIV-positive TB cases, all types, registered in 2013            | (49) | 2 438   |
| RR-/MDR-TB cases started on second-line treatment in 2012       | (54) | 432     |
| XDR-TB cases started on second-line treatment in 2012           | (64) | 11      |

| Laboratories 2014                                      |                 |
|--|-----------------|
| Smear (per 100 000 population)                         | 2.2             |
| Culture (per 5 million population)                     | 0.4             |
| Drug susceptibility testing (per 5 million population) | 0.3             |
| Sites performing Xpert MTB/RIF                         | 41              |
| Is second-line drug susceptibility testing available?  | Yes, in country |

| Financing TB control 2015                    |     |
|--|-----|
| National TB programme budget (US\$ millions) | 133 |
| % Funded domestically                        | 13% |
| % Funded internationally                     | 21% |
| % Unfunded                                   | 66% |


\* Ranges represent uncertainty intervals

\*\* Includes cases with unknown previous TB treatment history

\*\*\* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB


## Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence  
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients  
on CPT on ART

Treatment success rate (%)



New Retreatment  
New and relapse Retreatment, excluding relapse  
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally  
Unfunded

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2016-09-26

Data: [www.who.int/tb/data](http://www.who.int/tb/data)

# Myanmar

Population 2014

53 million

| Estimates of TB burden * 2014 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 28 (20–37)         | 53 (38–70)                    |
| Mortality (HIV+TB only)       | 4.1 (3.3–5.1)      | 7.7 (6.1–9.5)                 |
| Prevalence (includes HIV+TB)  | 240 (190–310)      | 457 (352–575)                 |
| Incidence (includes HIV+TB)   | 200 (180–220)      | 369 (334–406)                 |
| Incidence (HIV+TB only)       | 19 (15–24)         | 36 (28–44)                    |

|                               |            |
|-------------------------------|------------|
| Case detection, all forms (%) | 70 (64–78) |
|-------------------------------|------------|

| Estimates of MDR-TB burden * 2014              | New                 | Retreatment         |
|--|---------------------|---------------------|
| % of TB cases with MDR-TB                      | 5 (3.1–6.8)         | 27 (15–39)          |
| MDR-TB cases among notified pulmonary TB cases | 5 600 (3 500–7 700) | 3 400 (1 900–4 900) |

| TB case notifications 2014             | New ** | Relapse |
|--|--------|---------|
| Pulmonary, bacteriologically confirmed | 42 608 | 5 276   |
| Pulmonary, clinically diagnosed        | 70 305 | 3 650   |
| Extrapulmonary                         | 16 108 | 405     |

|  |                |
|--|----------------|
| <b>Total new and relapse</b>           | <b>138 352</b> |
| Previously treated, excluding relapses | 3 605          |
| <b>Total cases notified</b>            | <b>141 957</b> |

Among 138 352 new and relapse cases:  
36 301 (26%) cases aged under 15 years; male:female ratio: 1.6

| Reported cases of RR-/MDR-TB 2014        | New          | Retreatment   | Total ** |
|--|--------------|---------------|----------|
| Cases tested for RR-/MDR-TB              | 10 295 (24%) | 15 166 (117%) | 26 240   |
| Laboratory-confirmed RR-/MDR-TB cases    |              |               | 3 495    |
| Patients started on MDR-TB treatment *** |              |               | 1 537    |

| TB/HIV 2014   | Number | (%)  |
|---|--------|------|
| TB patients with known HIV status                                   | 56 133 | (40) |
| HIV-positive TB patients  | 6 412  | (11) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 4 666  | (73) |
| HIV-positive TB patients on antiretroviral therapy (ART)            | 2 319  | (36) |
| HIV-positive people screened for TB                                 | 54 178 |      |
| HIV-positive people provided with IPT                               | 2 997  |      |

| Treatment success rate and cohort size                    | (%)  | Cohort  |
|---|------|---------|
| New cases registered in 2013                              | (87) | 135 614 |
| Previously treated cases registered in 2013               | (71) | 7 147   |
| HIV-positive TB cases, all types, registered in 2013      |      |         |
| RR-/MDR-TB cases started on second-line treatment in 2012 | (79) | 443     |
| XDR-TB cases started on second-line treatment in 2012     |      |         |

| Laboratories 2014                                      |     |
|--|-----|
| Smear (per 100 000 population)                         | 0.9 |
| Culture (per 5 million population)                     | 0.3 |
| Drug susceptibility testing (per 5 million population) | 0.2 |
| Sites performing Xpert MTB/RIF                         | 38  |

Is second-line drug susceptibility testing available? Yes, outside country

| Financing TB control 2015                    |     |
|--|-----|
| National TB programme budget (US\$ millions) | 36  |
| % Funded domestically                        | 11% |
| % Funded internationally                     | 67% |
| % Unfunded                                   | 22% |


\* Ranges represent uncertainty intervals

\*\* Includes cases with unknown previous TB treatment history

\*\*\* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB


## Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence  
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients  
on CPT on ART

Treatment success rate (%)



New Retreatment  
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally  
Unfunded

# Philippines

Population 2014

99 million

| Estimates of TB burden * 2014 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 10 (9–11)          | 10 (9.1–11)                   |
| Mortality (HIV+TB only)       | 0.08 (0.055–0.11)  | 0.08 (0.06–0.11)              |
| Prevalence (includes HIV+TB)  | 410 (360–470)      | 417 (367–471)                 |
| Incidence (includes HIV+TB)   | 290 (250–320)      | 288 (254–324)                 |
| Incidence (HIV+TB only)       | 2.5 (2–3.2)        | 2.6 (2–3.2)                   |

|                               |            |
|-------------------------------|------------|
| Case detection, all forms (%) | 85 (76–97) |
|-------------------------------|------------|

| Estimates of MDR-TB burden * 2014              | New                 | Retreatment         |
|--|---------------------|---------------------|
| % of TB cases with MDR-TB                      | 2 (1.4–2.7)         | 21 (16–29)          |
| MDR-TB cases among notified pulmonary TB cases | 4 600 (3 300–6 300) | 6 500 (4 700–8 700) |

| TB case notifications 2014             | New **  | Relapse |
|--|---------|---------|
| Pulmonary, bacteriologically confirmed | 92 991  | 6 277   |
| Pulmonary, clinically diagnosed        | 139 950 |         |
| Extrapulmonary                         | 4 161   |         |

|  |                |
|--|----------------|
| <b>Total new and relapse</b>           | <b>243 379</b> |
| Previously treated, excluding relapses | 24 057         |
| <b>Total cases notified</b>            | <b>267 436</b> |

Among 97 578 new and relapse cases:  
12 191 (12%) cases aged under 15 years; male:female ratio: 1.8

| Reported cases of RR-/MDR-TB 2014        | New        | Retreatment  | Total ** |
|--|------------|--------------|----------|
| Cases tested for RR-/MDR-TB              | 4 415 (5%) | 20 196 (67%) | 27 287   |
| Laboratory-confirmed RR-/MDR-TB cases    |            |              | 3 000    |
| Patients started on MDR-TB treatment *** |            |              | 2 680    |

| TB/HIV 2014   | Number | (%)  |
|---|--------|------|
| TB patients with known HIV status                                   | 53 354 | (20) |
| HIV-positive TB patients  | 108    | (<1) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 20     | (19) |
| HIV-positive TB patients on antiretroviral therapy (ART)            | 53     | (49) |
| HIV-positive people screened for TB                                 | 5 995  |      |
| HIV-positive people provided with IPT                               |        |      |

| Treatment success rate and cohort size                          | (%)  | Cohort  |
|---|------|---------|
| New and relapse cases registered in 2013                        | (90) | 216 250 |
| Previously treated cases, excluding relapse, registered in 2013 | (86) | 2 924   |
| HIV-positive TB cases, all types, registered in 2013            |      |         |
| RR-/MDR-TB cases started on second-line treatment in 2012       | (43) | 1 798   |
| XDR-TB cases started on second-line treatment in 2012           | (10) | 10      |

| Laboratories 2014                                      |                 |
|--|-----------------|
| Smear (per 100 000 population)                         | 2.6             |
| Culture (per 5 million population)                     | 1.1             |
| Drug susceptibility testing (per 5 million population) | 0.2             |
| Sites performing Xpert MTB/RIF                         | 84              |
| Is second-line drug susceptibility testing available?  | Yes, in country |

| Financing TB control 2015                    |     |
|--|-----|
| National TB programme budget (US\$ millions) | 106 |
| % Funded domestically                        | 23% |
| % Funded internationally                     | 39% |
| % Unfunded                                   | 37% |


\* Ranges represent uncertainty intervals

\*\* Includes cases with unknown previous TB treatment history

\*\*\* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB


## Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence  
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients  
on CPT on ART

Treatment success rate (%)



New Retreatment  
New and relapse Retreatment, excluding relapse  
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally  
Unfunded

# Thailand

Population 2014

68 million

| Estimates of TB burden * 2014 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 7.4 (3.9–12)       | 11 (5.7–18)                   |
| Mortality (HIV+TB only)       | 4.5 (2.3–7.4)      | 6.6 (3.4–11)                  |
| Prevalence (includes HIV+TB)  | 160 (110–220)      | 236 (161–326)                 |
| Incidence (includes HIV+TB)   | 120 (61–190)       | 171 (90–276)                  |
| Incidence (HIV+TB only)       | 15 (7.8–24)        | 22 (12–36)                    |
| Case detection, all forms (%) | 59 (36–110)        |                               |

| Estimates of MDR-TB burden * 2014              | New               | Retreatment       |
|--|-------------------|-------------------|
| % of TB cases with MDR-TB                      | 2 (1.4–2.8)       | 19 (14–25)        |
| MDR-TB cases among notified pulmonary TB cases | 1 100 (780–1 600) | 1 100 (800–1 500) |

| TB case notifications 2014             | New ** | Relapse |
|--|--------|---------|
| Pulmonary, bacteriologically confirmed | 34 394 | 1 969   |
| Pulmonary, clinically diagnosed        | 21 115 | 0       |
| Extrapulmonary                         | 10 244 | 0       |

|  |               |
|--|---------------|
| <b>Total new and relapse</b>           | <b>67 722</b> |
| Previously treated, excluding relapses | 3 896         |
| <b>Total cases notified</b>            | <b>71 618</b> |

Among 34 394 new cases:  
119 (<1%) cases aged under 15 years; male:female ratio: 2.5

| Reported cases of RR-/MDR-TB 2014        | New         | Retreatment | Total ** |
|--|-------------|-------------|----------|
| Cases tested for RR-/MDR-TB              | 4 370 (13%) | 2 209 (38%) | 9 580    |
| Laboratory-confirmed RR-/MDR-TB cases    |             |             | 506      |
| Patients started on MDR-TB treatment *** |             |             |          |

| TB/HIV 2014   | Number | (%)  |
|---|--------|------|
| TB patients with known HIV status                                   | 50 670 | (71) |
| HIV-positive TB patients  | 6 831  | (13) |
| HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) | 4 359  | (64) |
| HIV-positive TB patients on antiretroviral therapy (ART)            | 4 691  | (69) |
| HIV-positive people screened for TB                                 |        |      |
| HIV-positive people provided with IPT                               |        |      |

| Treatment success rate and cohort size                          | (%)  | Cohort |
|---|------|--------|
| New and relapse cases registered in 2013                        | (81) | 65 867 |
| Previously treated cases, excluding relapse, registered in 2013 | (66) | 1 812  |
| HIV-positive TB cases, all types, registered in 2013            | (67) | 7 665  |
| RR-/MDR-TB cases started on second-line treatment in 2012       |      |        |
| XDR-TB cases started on second-line treatment in 2012           |      |        |

| Laboratories 2014                                      |                 |
|--|-----------------|
| Smear (per 100 000 population)                         | 1.3             |
| Culture (per 5 million population)                     | 3.9             |
| Drug susceptibility testing (per 5 million population) | 1.5             |
| Sites performing Xpert MTB/RIF                         | 14              |
| Is second-line drug susceptibility testing available?  | Yes, in country |

| Financing TB control 2015                    |     |
|--|-----|
| National TB programme budget (US\$ millions) | 32  |
| % Funded domestically                        | 52% |
| % Funded internationally                     | 11% |
| % Unfunded                                   | 37% |


\* Ranges represent uncertainty intervals

\*\* Includes cases with unknown previous TB treatment history

\*\*\* Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having RR-/MDR-TB


## Tuberculosis profile

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence  
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients  
on CPT on ART

Treatment success rate (%)



New Retreatment  
New and relapse Retreatment, excluding relapse  
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally  
Unfunded

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.

Generated: 2016-09-26

Data: [www.who.int/tb/data](http://www.who.int/tb/data)

## TB Statistics of Non-High Burden Countries (2014)

| Population (1000)               |                                |        |        | Nepal     |        | Korea |             | Taiwan |             | Japan |              |
|---------------------------------|--------------------------------|--------|--------|-----------|--------|-------|-------------|--------|-------------|-------|--------------|
|                                 |                                |        |        | 28        |        | 50    |             |        |             | 127   |              |
| Incidence (Estimate)            | include. HIV                   | Number | 44     | 39 - 50   |        | 43    | 41 - 46     |        |             | 23    | 20 - 26      |
|                                 |                                | Rate   | 158    | 139-178   |        | 86    | 81-91       |        |             | 18    | 16 - 21      |
| Mortality                       | HIV+ only                      | Number | 1.5    | 1.2 - 1.9 |        | 0.51  | 0.44 - 0.59 |        |             | 0.099 | 0.089 - 0.12 |
|                                 |                                | Rate   | 5.4    | 4.2 - 6.7 |        | 2.6   | 2.2 - 3.0   |        |             | <0.1  | <0.1-<0.1    |
| Case detection Rate (%)         |                                | Number | 5.3    | 3.7 - 7.1 |        | 1.9   | 1.8 - 2.1   | 609    |             | 2.2   | 2.2 - 2.3    |
|                                 |                                | Rate   | 19     |           |        | 3.8   | 3.6 - 4.1   | 2.6    |             | 1.8   | 1.7 - 1.8    |
| MDT-TB (%)                      |                                |        |        |           |        | 93    | 88 - 99     |        |             | 84    | 75 - 96      |
|                                 | New                            |        |        |           |        | 2.7   | 2.1 - 3.4   | 3.2    |             | 0.7   | 0.42 - 1.1   |
|                                 | Retreatment                    |        | 15     | 10 - 23   |        | 14    | 10 - 19     | 8.2    |             | 9.8   | 7.1 - 13     |
|                                 | Survey year                    |        | 2,011  |           |        |       | 2,004       |        | 2005 - 2011 |       | 2,002        |
| Case notification               | New & Relapse                  | Number | 35,277 |           | 40,190 |       | 11,326      |        | 19,615      |       |              |
|                                 |                                | Rate   | 125    |           | 80     |       | 48          |        | 15          |       |              |
|                                 | New, Pulm, bacteriol confirmed |        | 15,947 |           | 18,784 |       |             |        | 12,120      |       |              |
|                                 | New, Pulm Clinical             |        | 8,445  |           | 9,350  |       |             |        | 2,061       |       |              |
| Treatment success (2013 Cohort) | New, Extrapulmonary            |        | 8,583  |           | 6,987  |       |             |        | 4,255       |       |              |
|                                 | %                              |        | 91     |           | 82     |       | 65          |        | 54          |       |              |
| Cohort size                     |                                |        | 33,877 |           | 40,794 |       |             |        | 15,941      |       |              |

Note : For Taiwan the data are for 2014 for notification, 2013 for mortality, and 2012 for Treatment results.

For Nepal, Korea and Japan figures are based on Global Tuberculosis Report 2015 (WHO).



សមាគមបង្ការជំងឺបាត់ដោយសារបាក់ស៊ីស្ទេម *Cambodia Anti-Tuberculosis Association*

Presentation and discussion of activities of partnerships



Cambodia Anti-TB Association  
Cambodia

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមបង្ការជំងឺបាត់ដោយសារបាក់ស៊ីស្ទេម *Cambodia Anti-Tuberculosis Association*

## About CATA (1)

- Background:**  
Cambodia Anti-Tuberculosis Association(CATA), a local NGO established in 2003, as a TB professional association of individual and institution committed to contribute to the fight against TB in Cambodia.
- Vision:**  
Make Cambodia free from TB and Lung Disease.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមបង្ការជំងឺបាត់ដោយសារបាក់ស៊ីស្ទេម *Cambodia Anti-Tuberculosis Association*

**Stop TB Partnership JAPAN**

Asian National Stop TB Partnership Forum  
"Community people's roles in End TB Strategy in Asia"  
United Nation University, Tokyo, Japan  
14 and 15 March, 2016

Dr. Khloeung Phally  
Mr. Chry Monyrath



We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមបង្ការជំងឺបាត់ដោយសារបាក់ស៊ីស្ទេម *Cambodia Anti-Tuberculosis Association*

## About CATA (2)

- Mission**  
Coordinate and advocate for TB free Cambodia and ensure social and community enabling environment through:
  - Promoting the institution and the individual to involve in Stop/End TB strategy
  - Information sharing, research and capacity building
  - Promoting the quality of effective prevention, early detection and treatment of Tuberculosis and Lung disease
  - Strengthening the effective enforcement of relevant laws, policies and guidelines.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមបង្ការជំងឺបាត់ដោយសារបាក់ស៊ីស្ទេម *Cambodia Anti-Tuberculosis Association*

## TB Burden in Cambodia

- Cambodia is still one of the 22 HBC with TB in the world
- Incidence rate of TB all forms in 2014 is 390/100,000\*.
- Prevalence rate of TB all forms in 2014 is 668/100,000\*.
- Prevalence rate of Sm+ for age 15 and over in 2011 is 272/100,000.
- Death rate 58/100,000\*

\* Global report 2015

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមបង្ការជំងឺបាត់ដោយសារបាក់ស៊ីស្ទេម *Cambodia Anti-Tuberculosis Association*

## About CATA (3)

- Goal**  
Strengthening the coverage and quality of TB services by increasing commitment of the institution and the individual and promoting the social and community environment.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រេកាបូនីយ៍ Cambodia Anti-Tuberculosis Association

## Current Projects

| Project Name   | Coverage Area                            |
|--|--|
| Public-Private Mix-DOT in Factory (work place)                     | 14 Factories, Phnom Penh                 |
| Active Case Finding among Elderly and other Vulnerable Communities | 12 Operational Districts in 8 Provinces. |

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រេកាបូនីយ៍ Cambodia Anti-Tuberculosis Association

## TB Control in Factory (2)

### 2. Current Methods:

- Trained peers to conduct peer contact activities.
- Conduct follow up (FU) meetings with peers
- Refer suspected TB case from factory to public health center
- Implement DOT in factories (work place)

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រេកាបូនីយ៍ Cambodia Anti-Tuberculosis Association

## (1) TB Control in Factory (PPM-DOT)



We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រេកាបូនីយ៍ Cambodia Anti-Tuberculosis Association

## TB Control in Factory (3)

### 3. Results:

- 14 garment factories were implemented.
- 11,553 workers were contacted by peer educators (11 months).
- 12 sessions of FU were conducted
- 108 TB suspects referred to HC (11mths).
- 10 TB cases registered (5s+, 4s- and 1EP) for treatment by DOT in factory (11 months).

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រេកាបូនីយ៍ Cambodia Anti-Tuberculosis Association

## TB Control in Factory (1)

### 1. Background:


- Factories, the poor ventilated settings where thousands of workers work and share room air are at high risk for TB
- Patients with TB symptoms may receive symptomatic treatment at the factories as factory clinics support only primary health care, leading to diagnostic delay.
- Untreated, some one with chronic TB may face being dismissed from employment due to frequent absenteeism, and bring additional hardship to the vulnerable family.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រេកាបូនីយ៍ Cambodia Anti-Tuberculosis Association

## TB Control in Factory (4)

### 4. Cases notified by TB types/years



| Year | EP | BK- | BK+ |
|------|----|-----|-----|
| 2007 | 1  | 0   | 5   |
| 2008 | 6  | 7   | 9   |
| 2009 | 2  | 2   | 6   |
| 2010 | 5  | 12  | 7   |
| 2011 | 4  | 4   | 7   |
| 2012 | 4  | 3   | 9   |
| 2013 | 5  | 3   | 9   |
| 2014 | 3  | 3   | 5   |

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រូស៊ីស កម្ពុជា *Cambodia Anti-Tuberculosis Association*

## TB Control in Factory (5)

**5. Lesson Learnt:**

- Lack of awareness raising activity, the discrimination among workers might be not reduced leading to less number of referral
- Limited budget for FU meeting with Peers is the cause of less peers' activity.
- TB patients can work regularly during the course of treatment( in the exception of 1<sup>st</sup> month therapy of smear positive cases).
- In congregated settings, one case treated can prevent hundreds of co-workers from TB

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រូស៊ីស កម្ពុជា *Cambodia Anti-Tuberculosis Association*

## Active Case Finding (2)

**2. Methods:**

- Active case finding using mobile teams equipped with a chest x-ray (CXR) and Xpert machine in 12 Operational Districts.
- 1 to 2 weeks before field operation, each health centre was visited for one day by the team:
  - Volunteers performed door to door **symptom screening** prior to CXR screening day.
  - TB suspects with a positive **CXR were then tested by Xpert MTB/RIF assay**
  - TB cases were registered and put on **treatment**
- Elderly were primarily targeted.
- Project yield and TB notification data were analysed to assess impact on treatment initiation.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រូស៊ីស កម្ពុជា *Cambodia Anti-Tuberculosis Association*



**(2) Active Case Finding Among Elderly & Other Vulnerable Community**

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រូស៊ីស កម្ពុជា *Cambodia Anti-Tuberculosis Association*

## Active Case Finding (3)

**3. Results (1):**

| Indicators   | Year 1 (2014)         |                 |     | Year 2 (2015)         |                 |     |
|--|-----------------------|-----------------|-----|-----------------------|-----------------|-----|
|  | Annual Planned Target | Achieved Target | %   | Annual Planned Target | Achieved Target | %   |
| (1) #of people screened                                    | 113735                | 68846           | 61% | 57810                 | 56996           | 99% |
| (2) #of TB suspects  | 21840                 | 11995           | 55% | 16830                 | 16043           | 95% |
| (3) #of people tested by TB X ray.                         | 18055                 | 11650           | 65% | 15810                 | 12147           | 77% |
| (4) #of TB suspects tested by Gene Xperts.                 | 3276                  | 2520            | 77% | 3478                  | 2084            | 60% |
| (5) #of people confirmed as SS +/B+ (yield SS+/B+)         | 663                   | 397             | 60% | 557                   | 334             | 60% |
| (6) #of people confirmed as TB all forms (yield all forms) | 1243                  | 1064            | 86% | 1265                  | 1094            | 86% |

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រូស៊ីស កម្ពុជា *Cambodia Anti-Tuberculosis Association*

## Active Case Finding (1)

**1. Backgrounds:**

- TB burden in Cambodia has decreased by > 50% by end 2015 compared to 1990 data.
- Cambodia still one of the highest TB prevalence in the world
  - Prevalence all form : 668 cases/100,000 population
  - Prevalence survey in 2011, TB burden in elderly is ≥3time higher than the general population.
  - Prevalence/Notification ratio in >55 years = 1.5
- Hypothesis: poor access to TB diagnosis and treatment

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

សមាគមអង្គការប្រឆាំងជំងឺប្រូស៊ីស កម្ពុជា *Cambodia Anti-Tuberculosis Association*

## Active Case Finding (4)

**3. Results (2):**

- 12 operational districts visited.
- 193 health facilities visited.
- 23,797 individuals screened by CXR.
- 4,604 (19.0%) individuals were tested using the Xpert MTB/RIF assay,
- Resulting in the detection of 731 (16%) MTB-positive patients.
- Total cases : 2158 (MTB positive + others)

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.



## Active Case Finding (4)

**3. Results (3):** New bacteriologically-positive notifications increased +119.2% for all ages and +262.7% for those ≥55 years during the ACF quarters compared to trend expected notifications.

Changes in new Bac+ and All Forms of TB treatment initiation and reporting in 4 Operational Districts of Year 1

|                                  | Patients Detected (Project Yield) | Actual Intervention Quarter Notifications | Trend Expected Intervention Quarter Notifications | Additional Notifications | Additional Notifications to Yield Ratio |
|----------------------------------|-----------------------------------|---|---|--------------------------|---|
| <b>New Bac+, All Ages</b>        | 319                               | 399                                       | 182   | 217 (+119.2%)            | 68.00%                                  |
| Ang Roka                         | 35                                | 58  | 24  | 34 (+141.7%)             | 97.10%                                  |
| Battambang                       | 68                                | 115                                       | 56  | 59 (+105.4%)             | 86.80%                                  |
| Kong Pisey                       | 110                               | 105                                       | 45  | 60 (+133.3%)             | 54.50%                                  |
| Sampovmeas                       | 106                               | 121                                       | 57  | 64 (+112.3%)             | 60.40%                                  |
| <b>New Bac+, ≥55 Years</b>       | 231                               | 243                                       | 67  | 176 (+262.7%)            | 76.20%                                  |
| Ang Roka                         | 29                                | 34  | 8   | 26 (+325.0%)             | 89.70%                                  |
| Battambang                       | 62                                | 61  | 13  | 48 (+369.2%)             | 66.70%                                  |
| Kong Pisey                       | 68                                | 71  | 24  | 47 (+195.8%)             | 69.10%                                  |
| Sampovmeas                       | 62                                | 77  | 22  | 55 (+250.0%)             | 88.70%                                  |
| <b>All Forms of TB, All Ages</b> | 893                               | 1,232                                     | 653   | 579 (+88.7%)             | 73.10%                                  |
| Ang Roka                         | 98                                | 152                                       | 68  | 84 (+122.4%)             | 69.40%                                  |
| Battambang                       | 230                               | 445                                       | 196   | 249 (+126.6%)            | 85.20%                                  |
| Kong Pisey                       | 318                               | 344                                       | 245   | 99 (+40.3%)              | 77.00%                                  |
| Sampovmeas                       | 247                               | 291                                       | 143   | 148 (+103.6%)            | 57.90%                                  |

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

## Active Case Finding (6)

**4. Lesson Learnt (2):**

- The conditions to replicate and expand the successful strategy are:
  - The combination of the team 1 and team 2 to work together for:
    - Increasing the number screened by CXR,
    - Saving fuel needed to supply 2 generators that operated separately.
    - Minimizing interruption of the operation due to unsafe power supply.
  - Procure a set of new CR machine to avoid interruption due to Prima console system error or broken.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

## Active Case Finding (4)

**3. Results (4):** NTP notifications in intervention period compared to expected notifications based on 3 year trend: New Bac+ notifications were +54.0% and +109.2% higher than expected for all ages and ≥55 years respectively.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

## Active Case Finding (7)

**4. Lesson Learnt (3):**

- The strategy used is likely appropriate for ACF but there are some constraints factors as following:
  - Road conditions are bad due to rainy season, causing difficulty to reach the HCs, leading to implementation time is short.
  - Elderly need to look after their grandchildren at home and sometime cannot come to HCs.
- The project screens/tests a lot of patients per day for a long period of time, so it may cause to damage the material. To avoid that and ensure the project run smoothly, CATA seeks fund to buy new equipment especially CR and X-ray machine for security.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

## Active Case Finding (5)

**4. Lesson Learnt (1):**

- The factors contributing to the success are the involvement from stakeholders and the trust to the project for its new technology, and quick diagnosis.
- The conditions for success to be continued are:
  - proper maintenance of all equipment to avoid being broken during implementation,
  - well calculation and implementation of project's resources supplied and demand
  - continue providing transport cost to the poor and those who live far away from HCs, and;
  - The use of communication skills and incentive provided to all stakeholders for better involvement is still key factors for success.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.

## Active Case Finding (8)

**5. Conclusion:**

- ACF using mobile teams was able to increase access to TB diagnosis, especially the elderly people.
- Compare to baseline data, the intervention can detect and treat many patients who previously missed routine TB services.
- We recommend to consider targeted ACF interventions in other settings where access to diagnosis and treatment is limited.

We are assisting the National Tuberculosis Control Program to reduce the morbidity and mortality among the Cambodian communities, especially the poor, caused by tuberculosis and lung disease.



**Thank You for Your Attention**

- Presentation and discussion of activities of partnerships



Forum Stop TB Partnership Indonesia  
Indonesia

...Indonesia...

**Indonesia is the biggest archipelago in the world that consist of 17,000 islands.**

**It also comprises administratively of :**

- **34 Provinces-416 districts and 98 cities-7,094 subdistricts-8,412 hamlets and 74,093 villages**



*presented during*

**"THE ASIAN NATIONAL  
STOP TB PARTNERSHIP FORUM",  
14 and 15 March 2016,  
Tokyo, Japan**

*prepared by:*

**Dr. Mariani Raksoprodjo & Dr Fitriani Manan**

...Indonesia...

**Current result :**

**Stop TB Partnership is only available in :**

- **1 city in west java province**
- **1 city and 2 districts in east java province**
- **4 districts in south Sulawesi Province**

**Based on those data, it is significantly obvious that "our homeworks" remain so many to accomplish.**

Indonesia

Area : 1,913,578.68  
Population :  
254,826,034



## Systematic Presentation

- 1. Name and Legal Corporate Status**
- 2. Short History**
- 3. Relationship with Other Organizations**
- 4. Members:**  
*Membership, Current Members*

## 5. Purposes

## 6. Activities

## 7. Current Challenges



## Name and Legal Corporate Status

**Name:** FORUM STOP TB PARTNERSHIP INDONESIA (FSTPI)

**Status:** Meanwhile, it remains temporarily as a Forum. Chairman of FSTPI is attempting to make the FSTPI a legal organization and formally registered to the Ministry of Legal and Human Rights, Republic of Indonesia

## History...

- **Address of Secretariat:** Jalan Sultan Iskandar Muda No. 66A  
Kebayoran Lama Utara  
Jakarta Selatan  
DKI Jakarta, Indonesia
- **Phone / Fax:** +62 21 739 74 94  
**Website:** [www.stopthindonesia.org](http://www.stopthindonesia.org)  
**Twitter:** @StopTBIndonesia  
**Facebook:** StopTBIndonesia
- **3-4 March 2014:** Host for The 2<sup>nd</sup> Forum of National Stop TB Partnership in South-East Asia, West Pacific and East Mediterranean Region  
  
This meeting was attended by 13 out of 14 invited countries (Myanmar regretted to come) and they were:

## Short History

- 30 May 2013: FSTPI was officially established and launched in Jakarta. This is a partnership group consisting of diverse organizations and individuals who have similar commitment in dealing with TB problems
- October 2013: Operational Guideline on FSTPI was published

## History...

- **SEA:** India, Bangladesh, Thailand Nepal and Indonesia
- **WP:** China, Philippines, Cambodia, Vietnam, South-Korea and Japan
- **EM:** Pakistan and Afghanistan



## RELATIONSHIP

### 5. Professional Organizations

- Indonesian Medical Doctor Association
- Indonesian Internist Association
- Indonesian Lung Doctor Association
- Indonesian Pediatric Association
- Indonesian Public Health Educators Association
- Indonesian National Nurses Association
- Indonesian Pharmacists Association
- Indonesian Midwives Association
- Indonesian Blood Transfusion Technician Association
- Indonesian Medical Laboratory Technology Expert Association

## RELATIONSHIP WITH OTHER ORGANIZATIONS

### MEMBERSHIP

### CURRENT NUMBER

Based on the List of FSTPI members at central level, there are 54 members that consist of:

#### 1. Government Group

- Ministry of Health
- Coordinating Ministry of Human Development and Culture
- Ministry of Legal and Human Rights
- Ministry of Defense
- Ministry of Manpower and Transmigration
- Centre of Health of National Army
- Centre of Medical and Health of Police Department

## RELATIONSHIP

### 6. Health Service Group

- Indonesian Hospital Association
- Indonesian Primary HealthCare Facilities and Clinics Association
- Gunung Sahari Clinical Laboratory

### 7. Academician Group

- Faculty of Public Health, University of Indonesia

### 8. University Students Group

- Asian Medical Students Association (AMSA Indonesia)
- Centre for Indonesian Medical Students Activities (CIMSIA)
- Students Executive Board of Faculty of Public Health, University of Indonesia

## RELATIONSHIP

### 2. State Owned and Private Companies Group

- BPJS (Universal Health Coverage) of Manpower
- BPJS (Universal Health Coverage) of Health
- Indonesian Entrepreneurs Association

### 3. Development Partners Group

- WHO Indonesia
- USAID
- DFAT
- KNCV
- FHI 360

### 4. CSO Group

- 9 CBO
- 7 FBO

## PURPOSES

- The main goal is to contribute in supporting the government on TB control
- The Forum is expected to be able to assist in overcoming the burden of national TB problem.
- In TB control, it will be difficult to do it if each group exercises it without good cooperation and coordination, as it can lead to the less optimal result.



### Activities

1. Quarterly plenary meeting
2. Facilitated meeting for developing national strategic plan on TB
3. Facilitated PHO/DHO/CSO to establish the forum Stop TB Partnership
4. Upload any news related TB / FSTPI into website
5. Share information to all of members (from Union, WHO, Global Stop TB Partnership)

### Current Challenges

4. Only around 30% of hospitals that have conducted Hospital DOTS Linkage.
5. Very limited budget allocated for TB Control from central and local governments.
6. Inappropriate TB facilities
7. Lack of understanding of community on TB

### Activities

6. Will Establish 5 working group in the forum :
  - Public communication
  - Advocacy
  - Community
  - Health service
  - Resource Mobilization



### Current Challenges

1. High Incident Rate and Prevalence Rate in Indonesia (based on the result of survey of 2013-2014)
  - Incidence Rate: 403 / 100,000 population
  - Prevalence Rate: 660 / 100,000 population

Total Population in Indonesia: ± 250 million
2. TB-related Issues:
  - The quality of DOTS should be improved
  - TB – MDR
  - TB-HIV
  - TB-DM
  - TB-with bad smoking habit
3. a. Recording and Reporting System for private physician are not yet formulated
- b. ISTC is not yet fully functioning






Presentation and discussion of activities of partnerships



## Stop TB Partnership Korea Korea

### <History of Korean TB situation>



## INTRODUCTION OF STOP TB PARTNERSHIP KOREA



Hongjo Choi, MD. PhD  
(KNTA, KIT)

### Name and legal corporate status

- Name : STOP-TB Partnership Korea(STBK)
- Legal corporate Status : None
  - Secretariat of STBK was installed under Korean National TB Association in 2009

### Table of Contents

1. Name and legal corporate status
2. Short history
3. Relationship with other organizations
4. Members: Membership, Current number
5. Purposes
6. Activities
7. Current challenges


### Short history

#### <Progress>

- 2008. 3** : Announcement of establishment / operation plan of the STOP-TB Partnership KOREA by the Ministry of Health and Welfare and Korean Center for Disease Control
- 2009. 6** : Establishment of the STBK's Secretariat under Korean National Tuberculosis Association
- 2010. 3** : Formal registration as the national cooperation partner of WHO Stop TB Partnership
- 2010. 12** : STBK inaugurated with 19 partners  
(Chairperson : Sook Mi Son, , Member of National Assembly)
- 2012. 11** : Hold 1<sup>st</sup> forum of national to stop western pacific & south-east asia regions
- 2015. 9** : Appointment 2<sup>nd</sup> chairperson, Myung Yeon Kim, Member of National Assembly
- 2016. 3** : 44 organizations and almost 60,000 individual partner take part in




## &lt;STBK Organization Chart&gt;



## &lt;Business Implementation System&gt;



- TB prevention education and support for the vulnerable, particularly, migrants and homeless people
- Development and promotion of tuberculosis elimination projects among underdeveloped countries and exchange programs for global & National STOP-TB Partnership
- Establishment of cooperative system to raise social awareness and participation into the domestic and global plan to stop TB.



## &lt;Advocacy&gt;



TV Documentary production for Improving TB Awareness



A commemorative event on the "World TB day"

## &lt;Advocacy&gt;




Policy forum to support efficient TB patient care



Monthly webzine publication and e-mail service

## &lt;Pilot programs to support homeless TB patients&gt;



## &lt;Advocacy&gt;



Appoint the representatives of 12 national communities as foreign TB honorary ambassador



Production of various IEC materials

## &lt;Education&gt;



Health lecture for TB high risk group such as the immigrants, homeless



STOP-TB Camp for youth

## &lt;Support for The Vulnerable population&gt;



Providing free TB X-ray screening joint with TB related partners during multicultural festival for the immigrants



Providing treatment expense for MDR-TB Patients

## &lt;International Cooperation&gt;



Project for Korea-Mongolia Anti-TB Collaboration in Ulaanbaatar



1<sup>st</sup> forum of national to stop TB western pacific & south-east Asia regions

#### Current challenges

- Development and vitalization of various tuberculosis eradication activities joint with partners to support NTP
- Improvement of sustainability STOP-TB Partnership Korea through developing unique fundraising method besides government aid
- Participating in active international tuberculosis eradication movement through the reinforcement of global cooperation capability by developing specific cooperation project and reinforcing link with other national partnership

Presentation and discussion of  
activities of partnerships



**MYANMAR MATERNAL AND  
CHILD WELFARE ASSOCIATION**  
Myanmar

*This presentation includes;*

- Brief information about MMCWA
- MMCWA's participation in community based TB care activities
  - *Self-reliance Approach*
    - ✓ Target areas
    - ✓ Methodology
    - ✓ Achievements
  - *Project Approach- CBTBC Project in collaboration with National TB Program (NTP) and Global Fund (Round-9)*
    - ✓ Target areas
    - ✓ Methodology
    - ✓ Achievements and challenges

4

## Asian National Stop-TB Partnership Forum

Tokyo, Japan

14-15<sup>th</sup> March, 2016

### Profile of MMCWA

✳ Myanmar Maternal and Child Welfare  
Association

Established since 30th April 1991


(according to law No: 21/90 – November 9<sup>th</sup>, 1990)

✳ Non-profit Voluntary Organization

5

5

Activities on Prevention and Control Measures of TB  
by  
MYANMAR MATERNAL AND CHILD WELFARE ASSOCIATION



14-15th March, 2016  
Tokyo, Japan

Daw Thazin Nwe  
President  
MMCWA

### Mission Statement

The Myanmar Maternal and Child Welfare Association is a voluntary organization dedicated to serve the Myanmar Society in promoting the health and well-being of mothers and children with the aim to improve the quality of life of the people.

6

6



## Objective




To carry out activities related to development of health, education, economic and social aspects of beneficiaries with priority to the grassroots level residing in wards and villages.

7

## Health Activities

10

### MMCWA Organizational Structure



8

### Provision of Community based health care services

|  |                                    |
|--|------------------------------------|
| Health Education                                       | Programme for Congenital Defect    |
| <b>Prevention and Control of Communicable diseases</b> | Eye Care Activities                |
| Programme for Chronic Non-communicable diseases        | Environmental Health               |
| Safe motherhood programme                              | Anti Tobacco activities            |
| Nutrition Programme                                    | Programme for Traditional Medicine |
| Immuization programme                                  | Capacity Building Programme        |

11

### MMCWA activities in line with its objectives

1. Health Activities
2. Educational Activities
3. Economic Activities
4. Social Activities

9

9

### Prevention and control of communicable diseases (HIV/AIDS, Malaria, TB, Leprosy, other infectious d/s..)

#### Health Education

- IEC dissemination
- Mass Media
- Community health talks
- Outreach round table talks
- Early Case Detection
- Referral
- Support for care and treatment

12

## Educational Activities

13

## Formal Education



Stationary Support to needy students



School Enrollment Week-Community Mobilization

## Educational activities

1. Early Childhood Development Centre (ECCD)
2. Participation in mobilization for School enrollment week
3. Stationeries, Uniforms and Financial Assistance for Formal Education
4. Adult Literacy
5. Evening classes

14

## Non-formal Education



3-R Classes



Continuous Learning Initiative for Adult Literacy

17

## Early Childhood Care and Development (ECCD)

### Activities

- ❖ Establishing holistic development from transition period of the children
- ❖ Creating opportunities for income generation for mothers
- ❖ Provision of parenting education
- ❖ Pre-school Teacher training

In 2014,

Number of Pre-school - 730  
Children (male) - 12349  
(female) - 15317

Number of Day Nursery - 39  
Children (male) - 574  
(female) - 738



**Libraries – 12873 numbers**  
**Community learning Centre – 3260 numbers**



Provided Books to Libraries

## Economic Activities

19

## Social Activities

22

### Income Generation Programme

1. Provision of vocational training courses(VCT) on sewing, knitting, cooking etc.
2. Micro-credit small loan scheme
3. Financial assistance for small household farming, agriculture and small scale home industries
4. Finding Job Opportunities



20

Micro-credit small loan scheme

### Social activities

- Elderly Care Program ( Home based care services for physical & psychosocial well-being)
- Bringing social support to orphanages and vulnerable group
- Maxillofacial correction to promote self esteemed for cleft children
- Promoting and assisting civic duty and cultural heritage for future generation
- Risk management and rapid response in time of disaster

23



Training on Embroidering  
Tapestry

Training on Basic Computer  
Skills


### MMCWA participation in Elderly Care Activities

#### Approaches

1. Self reliance Approach  
-by MMCWA (Central)  
/State & Regional /Township  
MCWA supervisory committees
2. Project Approach  
(MMCWA+DSW)  
(MMCWA Funding)







### Collaborating Agencies of MMCWA

#### Government sector

1. Ministry of Health
2. Ministry of Education
3. Ministry of Social Welfare
4. Ministry of Internal Affairs

#### International

1. WHO
2. UNICEF
3. IPPF
4. UNFPA
5. UNAIDS
6. JOICFP
7. GGA

28



Conducting Home Based  
Medical Care

Provision of eye care for elderly

### MMCWA Community Based TB Care Activities

29

### Participation in relief matters at the effected area of disasters



Donation for Flooded Townships in  
Kalay and Tamu

Preparation Dignity Kits for Disaster-risk  
areas at MMCWA HQs

27

### Approaches

1. Self reliance Approach  
-by MMCWA (Central)/State & Regional / Township  
MCWA supervisory committees
2. Project Approach  
(MMCWA+NTP)  
(Global Fund Round-9 Funding)




### MMCWA Self reliance TB Care Activities

- Target - 15 States and Regions(330 townships)
- Methodology
  - Dissemination Health Talks on prevention of TB
  - Referral of presumptive TB cases
  - MMCWA volunteers' participation on DOTs programme

31


### Community based TB Care (MMCWA+NTP+GF) (Townships - 69 townships)

2011 - 37 townships  
2012-2015 - 69 townships



34

### MMCWA Self reliance TB Care Activities(Cont;)



32



### Activities

- (1) Central Training of trainers on Community TB Care (Naypyitaw) (x 2 days) (1 volunteer/tsp)
- (2) Township Multiplier Training for Community volunteer on DOTs (x 2 days) (30 volunteer/tsp)
- (3) TB case finding and/or treatment activities at community level
- (4) Community education session
- (5) Half yearly evaluation meeting for community volunteer at respective township level

36

- (6) Central Annual Evaluation Meeting at MMCWA HQ (Yearly)
- (7) Refresher Training for community volunteers at MMCWA HQ (once in 3 year)

#### Supervision

- (1) Supervision from Central to State/Regional level  
- One visit per year to the respective State/Regions
- (2) Supervision from Districts to Townships level  
- One visit per year to the respective townships

37

#### Annual Evaluation Meeting



40

Form 1. Reporting form and register

Section 1: GENERAL INFORMATION (NAME, ADDRESS, CONTACT, etc.)

Section 2: TB CASES (Suspected, Confirmed, Treated, etc.)

Section 3: TB PATIENTS (Name, Age, Sex, etc.)

Section 4: TB TREATMENT (Drug, Duration, etc.)

Section 5: TB OUTCOMES (Cured, Died, etc.)

Section 6: TB PREVENTION (Vaccination, etc.)

Section 7: TB CONTROL (Screening, etc.)

Section 8: TB EDUCATION (Health talks, etc.)

Section 9: TB SUPPORT (Financial, etc.)

Section 10: TB MONITORING (Regular check-ups, etc.)

Section 11: TB EVALUATION (Annual review, etc.)

Section 12: TB REPORTING (Monthly, quarterly, etc.)

Section 13: TB RECORDS (Maintain, etc.)

Section 14: TB DATA (Collect, etc.)

Section 15: TB ANALYSIS (Interpret, etc.)

Section 16: TB ACTION (Plan, etc.)

Section 17: TB IMPLEMENTATION (Execute, etc.)

Section 18: TB EVALUATION (Assess, etc.)

Section 19: TB REPORTING (Report, etc.)

Section 20: TB RECORDS (Update, etc.)

Section 21: TB DATA (Analyze, etc.)

Section 22: TB ANALYSIS (Conclude, etc.)

Section 23: TB ACTION (Implement, etc.)

Section 24: TB IMPLEMENTATION (Monitor, etc.)

Section 25: TB EVALUATION (Review, etc.)

Section 26: TB REPORTING (Summarize, etc.)

Section 27: TB RECORDS (Archive, etc.)

Section 28: TB DATA (Present, etc.)

Section 29: TB ANALYSIS (Discuss, etc.)

Section 30: TB ACTION (Recommend, etc.)

Section 31: TB IMPLEMENTATION (Follow-up, etc.)

Section 32: TB EVALUATION (Finalize, etc.)

Section 33: TB REPORTING (Distribute, etc.)

Section 34: TB RECORDS (Secure, etc.)

Section 35: TB DATA (Store, etc.)

Section 36: TB ANALYSIS (Share, etc.)

Section 37: TB ACTION (Communicate, etc.)

Section 38: TB IMPLEMENTATION (Engage, etc.)

Section 39: TB EVALUATION (Celebrate, etc.)

Section 40: TB REPORTING (Acknowledge, etc.)

Section 41: TB RECORDS (Preserve, etc.)

Section 42: TB DATA (Protect, etc.)

Section 43: TB ANALYSIS (Validate, etc.)

Section 44: TB ACTION (Promote, etc.)

Section 45: TB IMPLEMENTATION (Sustain, etc.)

Section 46: TB EVALUATION (Improve, etc.)

Section 47: TB REPORTING (Innovate, etc.)

Section 48: TB RECORDS (Integrate, etc.)

Section 49: TB DATA (Automate, etc.)

Section 50: TB ANALYSIS (Simplify, etc.)

Section 51: TB ACTION (Empower, etc.)

Section 52: TB IMPLEMENTATION (Strengthen, etc.)

Section 53: TB EVALUATION (Transform, etc.)

Section 54: TB REPORTING (Revitalize, etc.)

Section 55: TB RECORDS (Reconstruct, etc.)

Section 56: TB DATA (Reinvent, etc.)

Section 57: TB ANALYSIS (Reimagine, etc.)

Section 58: TB ACTION (Reorganize, etc.)

Section 59: TB IMPLEMENTATION (Recharge, etc.)

Section 60: TB EVALUATION (Reconnect, etc.)

Section 61: TB REPORTING (Rebuild, etc.)

Section 62: TB RECORDS (Renew, etc.)

Section 63: TB DATA (Recover, etc.)

Section 64: TB ANALYSIS (Refine, etc.)

Section 65: TB ACTION (Refocus, etc.)

Section 66: TB IMPLEMENTATION (Reform, etc.)

Section 67: TB EVALUATION (Reassert, etc.)

Section 68: TB REPORTING (Reassess, etc.)

Section 69: TB RECORDS (Reconfigure, etc.)

Section 70: TB DATA (Reorient, etc.)

Section 71: TB ANALYSIS (Reopen, etc.)

Section 72: TB ACTION (Restart, etc.)

Section 73: TB IMPLEMENTATION (Reignite, etc.)

Section 74: TB EVALUATION (Reinvigorate, etc.)

Section 75: TB REPORTING (Reignite, etc.)

Section 76: TB RECORDS (Reignite, etc.)

Section 77: TB DATA (Reignite, etc.)

Section 78: TB ANALYSIS (Reignite, etc.)

Section 79: TB ACTION (Reignite, etc.)

Section 80: TB IMPLEMENTATION (Reignite, etc.)

Section 81: TB EVALUATION (Reignite, etc.)

Section 82: TB REPORTING (Reignite, etc.)

Section 83: TB RECORDS (Reignite, etc.)

Section 84: TB DATA (Reignite, etc.)

Section 85: TB ANALYSIS (Reignite, etc.)

Section 86: TB ACTION (Reignite, etc.)

Section 87: TB IMPLEMENTATION (Reignite, etc.)

Section 88: TB EVALUATION (Reignite, etc.)

Section 89: TB REPORTING (Reignite, etc.)

Section 90: TB RECORDS (Reignite, etc.)

Section 91: TB DATA (Reignite, etc.)

Section 92: TB ANALYSIS (Reignite, etc.)

Section 93: TB ACTION (Reignite, etc.)

Section 94: TB IMPLEMENTATION (Reignite, etc.)

Section 95: TB EVALUATION (Reignite, etc.)

Section 96: TB REPORTING (Reignite, etc.)

Section 97: TB RECORDS (Reignite, etc.)


Section 98: TB DATA (Reignite, etc.)

Section 99: TB ANALYSIS (Reignite, etc.)

Section 100: TB ACTION (Reignite, etc.)

39

#### Indicators



41

Form 1. Reporting form and register

Section 1: GENERAL INFORMATION (NAME, ADDRESS, CONTACT, etc.)

Section 2: TB CASES (Suspected, Confirmed, Treated, etc.)

Section 3: TB PATIENTS (Name, Age, Sex, etc.)

Section 4: TB TREATMENT (Drug, Duration, etc.)

Section 5: TB OUTCOMES (Cured, Died, etc.)

Section 6: TB PREVENTION (Vaccination, etc.)

Section 7: TB CONTROL (Screening, etc.)

Section 8: TB EDUCATION (Health talks, etc.)

Section 9: TB SUPPORT (Financial, etc.)

Section 10: TB MONITORING (Regular check-ups, etc.)

Section 11: TB EVALUATION (Annual review, etc.)

Section 12: TB REPORTING (Monthly, quarterly, etc.)

Section 13: TB RECORDS (Maintain, etc.)

Section 14: TB DATA (Collect, etc.)

Section 15: TB ANALYSIS (Interpret, etc.)

Section 16: TB ACTION (Plan, etc.)

Section 17: TB IMPLEMENTATION (Execute, etc.)

Section 18: TB EVALUATION (Assess, etc.)

Section 19: TB REPORTING (Report, etc.)

Section 20: TB RECORDS (Update, etc.)

Section 21: TB DATA (Analyze, etc.)

Section 22: TB ANALYSIS (Conclude, etc.)

Section 23: TB ACTION (Implement, etc.)

Section 24: TB IMPLEMENTATION (Monitor, etc.)

Section 25: TB EVALUATION (Review, etc.)

Section 26: TB REPORTING (Summarize, etc.)

Section 27: TB RECORDS (Archive, etc.)

Section 28: TB DATA (Present, etc.)

Section 29: TB ANALYSIS (Discuss, etc.)

Section 30: TB ACTION (Recommend, etc.)

Section 31: TB IMPLEMENTATION (Follow-up, etc.)

Section 32: TB EVALUATION (Finalize, etc.)

Section 33: TB REPORTING (Distribute, etc.)

Section 34: TB RECORDS (Secure, etc.)

Section 35: TB DATA (Store, etc.)

Section 36: TB ANALYSIS (Share, etc.)

Section 37: TB ACTION (Communicate, etc.)

Section 38: TB IMPLEMENTATION (Engage, etc.)

Section 39: TB EVALUATION (Celebrate, etc.)

Section 40: TB REPORTING (Acknowledge, etc.)

Section 41: TB RECORDS (Preserve, etc.)

Section 42: TB DATA (Protect, etc.)

Section 43: TB ANALYSIS (Validate, etc.)

Section 44: TB ACTION (Promote, etc.)

Section 45: TB IMPLEMENTATION (Sustain, etc.)

Section 46: TB EVALUATION (Improve, etc.)

Section 47: TB REPORTING (Innovate, etc.)

Section 48: TB RECORDS (Integrate, etc.)

Section 49: TB DATA (Automate, etc.)

Section 50: TB ANALYSIS (Simplify, etc.)

Section 51: TB ACTION (Empower, etc.)

Section 52: TB IMPLEMENTATION (Strengthen, etc.)

Section 53: TB EVALUATION (Transform, etc.)

Section 54: TB REPORTING (Revitalize, etc.)

Section 55: TB RECORDS (Reconstruct, etc.)

Section 56: TB DATA (Reinvent, etc.)

Section 57: TB ANALYSIS (Reimagine, etc.)

Section 58: TB ACTION (Reorganize, etc.)

Section 59: TB IMPLEMENTATION (Recharge, etc.)

Section 60: TB EVALUATION (Reconnect, etc.)

Section 61: TB REPORTING (Rebuild, etc.)

Section 62: TB RECORDS (Renew, etc.)

Section 63: TB DATA (Recover, etc.)

Section 64: TB ANALYSIS (Refine, etc.)

Section 65: TB ACTION (Refocus, etc.)

Section 66: TB IMPLEMENTATION (Reform, etc.)

Section 67: TB EVALUATION (Reassert, etc.)

Section 68: TB REPORTING (Reassess, etc.)

Section 69: TB RECORDS (Reconfigure, etc.)

Section 70: TB DATA (Reorient, etc.)

Section 71: TB ANALYSIS (Reopen, etc.)

Section 72: TB ACTION (Restart, etc.)

Section 73: TB IMPLEMENTATION (Reignite, etc.)

Section 74: TB EVALUATION (Reinvigorate, etc.)

Section 75: TB REPORTING (Reignite, etc.)

Section 76: TB RECORDS (Reignite, etc.)

Section 77: TB DATA (Reignite, etc.)

Section 78: TB ANALYSIS (Reignite, etc.)

Section 79: TB ACTION (Reignite, etc.)

Section 80: TB IMPLEMENTATION (Reignite, etc.)

Section 81: TB EVALUATION (Reignite, etc.)

Section 82: TB REPORTING (Reignite, etc.)

Section 83: TB RECORDS (Reignite, etc.)

Section 84: TB DATA (Reignite, etc.)

Section 85: TB ANALYSIS (Reignite, etc.)

Section 86: TB ACTION (Reignite, etc.)

Section 87: TB IMPLEMENTATION (Reignite, etc.)

Section 88: TB EVALUATION (Reignite, etc.)

Section 89: TB REPORTING (Reignite, etc.)

Section 90: TB RECORDS (Reignite, etc.)

Section 91: TB DATA (Reignite, etc.)

Section 92: TB ANALYSIS (Reignite, etc.)

Section 93: TB ACTION (Reignite, etc.)

Section 94: TB IMPLEMENTATION (Reignite, etc.)

Section 95: TB EVALUATION (Reignite, etc.)

Section 96: TB REPORTING (Reignite, etc.)

Section 97: TB RECORDS (Reignite, etc.)


Section 98: TB DATA (Reignite, etc.)

Section 99: TB ANALYSIS (Reignite, etc.)

Section 100: TB ACTION (Reignite, etc.)

39

#### MMCWA contribution to National TB Program(NTP)



Source: NTP

### Supervision from Central to Mon State



43

#### Strengths

- 1 MMCWA Volunteers reach to the gross-root level
- 2 Volunteers are enthusiastic and energetic in finding new cases and referral
- 3 MCWA Volunteers participate in Home-based Care for providing DOTS
- 4 Community participation are active;  
- Interested in Health Talks on TB preventive and control measures

#### Challenges

- 1 Supervision from District to township level reports are not receiving regularly.
- 2 Attrition within the ToT volunteers
- 3 Reporting system sometimes weak, not received in time.
- 4 Need patient support and transportation fees for patients

### Supervision from Central to Mandalay Region



44

### Volunteerism

Performing an act of kindness , freely giving of talent, time, effort for the simple fulfillment of community expectations.



### Training of Trainers(ToT) Refresher Training



45



Thank You



## Presentation and discussion of activities of partnerships



Japan-Nepal Health & TB Research Association  
Nepal

### Scenario:2015

- Major Public Health Problem
- Priority I Programme of the Government

|                                    |                |
|------------------------------------|----------------|
| • Population                       | : 27 million   |
| • Incidence rate (all TB cases)    | : 163 /100,000 |
| • Prevalence rate (all TB cases)   | : 241/ 100,000 |
| • Mortality rate                   | : 20/100,000   |
| • TB patients co-infected with HIV | : 2.4%         |
| • Proportion of MDR-TB             |                |
| ▪ New cases                        | : 2.2%         |
| ▪ Previously treated cases         | : 16%          |




Ram Sharan Gopali (MPH)  
Executive Director

## Who we are.....?

JANTRA is a non-profitable, public service oriented non-government organization

JANTRA is affiliated with Research Institute of Tuberculosis/Japan Anti-Tuberculosis Association

JANTRA is a member of Nepal TB Control-Network



### Basic Facts of Nepal

Nepal is a landlocked country located in the WHO South Asian region at the edge of the Himalaya mountains between India and the Peoples Republic of China

| Area              | 147,181 Sq. km |
|-------------------|----------------|
| Region            | 5              |
| Zone              | 14             |
| District          | 75             |
| Treatment Centre  | 1140           |
| Sub-treatment     | 2907           |
| Microscope Centre | 554            |
| Gene-Xpert Center | 22             |
| MDR Centre        | 13             |
| MDR Sub-Cen.      | 71             |



### Mission

To franchise in the prevention/control of Tuberculosis, Public Health and Social Development issues in Nepal.

#### Areas of Intervention;

- Policy and Advocacy at all level
- Community System Strengthening (CSS)
- Knowledge Management
- Partnership and networking (Nationally & Internationally)



## Our Steps for.....

- To enhance collaboration between TB patients, NGO's/CSO's, Research Institutions, Universities, Government line agencies
- To care and support for those who are infected and affected by TB, for the purpose of controlling and caring all forms of TB (TB, DR, TB/HIV)
- To reduce stigma and discrimination related with TB and its co-infection
- To improve community health through innovative models up to grassroots level by knowing the local contexts

## 2. Community engagement and their role

- Active case finding
- door to door visit by volunteers
- monthly meeting for TB volunteers
- School health program
- Volunteer Trust Fund
- Referral and cross referral of presumptive cases
- Tracing of loss to follow up TB patients
- Organize advocacy and social mobilization



10

## Current Projects



## 3. Net-working and Social Protection

- Communication and social mobilization activities for factory workers and vulnerable groups
- Strengthening coordination & collaboration with partners and synergy
- Tangible & intangible support for TB patients who are in need
- Initiation of TB patients club
- Empowerment of TB patients
- Enhanced understanding on Patient Character among service stakeholders and service providers



11

## 1. Quality DOTS services is provided for TB patients

- Innovative DOTS and Sputum examination (8:00 AM-4/5 PM)
- Referral, cross-referral and counter referral from community and private sectors
- Operational partnership with partners and CSO's
- Capacity building of key stakeholders (Health care providers public and private), volunteers, local administrative authorities



9


## 4. Strengthening Urban TB control

- Organizing regular meeting with stakeholders and partners
- Carrying-out joint supportive supervision with concerned stakeholders and immediate feedback mechanism
- Establishment of Volunteers Trust fund
- Support for poor TB patients who are not eligible in public social protection scheme
- Logistic management support




12

### DOTS service & SPUTUM EXAMINATION (2014/2015)




### Hotline Consultation

Consultation from Hotline telephone




### Case finding




### Key Q & A of hotline consultation

- Sign and Symptoms of Tuberculosis
- Location of DOTS Centre
- Venue of Microscopic Camps
- Information about daily DOTS and assurance of treatment
- Minor side effects
- Clinic opening time

### Hotline Consultation



### Trend of Treatment Success Rate




### Systematic Screening of target populations & microscopy camps

- Community-Based;
  - TB screening/presumptive TB identification/examination/treatment enrollment and contact investigation
  - Awareness raising
- PPM
  - Strengthen cross referral mechanism
  - Refer TB suspects to microscopic camp and other laboratories
  - Collaboration with private laboratory
- Meaningful involvement and mobilization of health workers (Public and Private and volunteers)



## Case finding framework




## Intervention

- Mapping of IDP s Camps
- Capacity building of Volunteers and key stakeholders
- Presumptive TB Case identification
- Sputum sample collection, sputum transportation & Test by Gene Xpert
- Chest Camp
- Treatment enrollment and follow up




## TB REACH (WAVE 4) Achievement From July 16, 2014 to November 15, 2015



## Post Disaster Recovery TB Program

Sep 2015- 20 Jan 2016



## Post Disaster Recovery Project

### Thematic Program Thrust-

### Early TB Case finding

### Target Beneficiaries-

Internally Displaced People of Kathmandu valley and Sindhupalchok district



## Lesson Learnt .....

- **Support from NTP:**
  - ✓ leads to sound implementation of the planned activities
- **Proper Orientation & consistent follow-up:**
  - ✓ To continue engagement of stakeholders (sample transportation from community to Microscopy Centre)
- **Intensive Advocacy Programme:**
  - ✓ More partners are interested to collaborate (local CBOs shows their interest for the collaboration)





## Lesson Learnt.....

- **Highly enthusiastic and committed volunteer;**
  - ✓ Leads to productive and sustainable programme in the community
- **Establishment of Patients club;**
  - ✓ Leads to effective contact tracing and peer education in the community
- **Consistent IEC/BCC Programme:**
  - ✓ To change service seeking behavior



## Acknowledgements

- National Tuberculosis Centre
- Research Institute of Tuberculosis/JATA
- UNOPS/Stop TB Partnership
- Global Affairs, Canada
- World Health Organization
- Regional Health Directorate Office
- District (Public) Health Offices
- Urban Health Clinics
- Health care Providers (Public & Private)
- Female Community Health Volunteers
- TB Patients and Family members

## Supportive Supervision & Result based monitoring

- Result based M&E and discussion with NTC
- Regular follow-up and monitoring from the RHD and respective project districts
- Project review and assessment from the TB REACH & RIT/JATA



Thank you

## Issues to be address;

- Sustainability and ownership
- Compatibility of TB Program inline with Sustainable Development Goal.
- Factor affecting TB Treatment and its success; co-morbidity for instance- diabetes, malnutrition etc
- Funding gap
- Logistic, documentation and monitoring.
- Research and development ; TB and Gender, PPM, Community Engagement, UHC

## Presentation and discussion of activities of partnerships



RIT/JATA Philippines, Inc  
Philippines

## RIT/JATA Philippines, Inc.

- Local-based NGO
- Established in 2008
- 7 staff

## RIT/ JATA Philippines, Inc. Activities and Accomplishments

STOP TB Partnership Forum – Asia  
March 14-15, 2016


## Accreditation/Membership


- Securities and Exchange Commission
- Philippine Council for NGO Certification
- NTP – Technical Working Group

## About us....

Research Institute of Tuberculosis /  
Japan Anti-Tuberculosis Association  
Philippines, Inc.  
(RIT/ JATA Philippines, Inc.)

## RIT/JATA (Organizational tree)







**Vision:**

TB- Free Philippines



**Mission:**

To contribute to the NTP of the Philippines in their goal of ensuring that quality TB services are available, accessible and affordable for all TB patients.



**PhilPACT Strategies**

- Strategy 5: Address MDR-TB, TB/HIV and the needs of vulnerable populations
- Strategy 6: Regulate and make available quality TB diagnostic tests and drugs
- Strategy 7: Certify and accredit TB care providers
- Strategy 8: Secure adequate funding and improve allocation and efficiency of fund utilization.



**Objective:**

To improve the access of the community to quality DOTS implementation by strengthening the linkage between GOs and NGOs/private organizations


**THE TUBERCULOSIS PROJECT IN SOCIO-ECONOMICALLY URBAN AREAS IN METRO MANILA, THE PHILIPPINES**  
2008- June 2011

Funded by : Ministry of Foreign Affairs

**PhilPACT Strategies**






- Strategy 1: Localize implementation of TB Control
- Strategy 2: Monitor health system performance
- Strategy 3: Engage both public and private TB care providers
- Strategy 4: Promote and strengthen positive behavior of communities




**TB CONTROL AND PREVENTION PROJECT IN SOCIO-ECONOMICALLY UNPRIVILEGED AREAS IN METRO MANILA, THE PHILIPPINES**  
2011- June 15, 2014


Funded by : Japan International Cooperation Agency







## Capacity Building

Basic TB DOTS Training




Infection Control Training






Basic DSSM Training for Medical Technologist




Appreciation Course for CXR

Research Institute of Tuberculosis/  
National Center for Tuberculosis & Respiratory Infections, Inc.

Orientation of CHV on Basic STI HIV and AIDS Education





CHV Assembly








Research Institute of Tuberculosis/  
National Center for Tuberculosis & Respiratory Infections, Inc.

## Interpersonal Communication and Counselling


Research Institute of Tuberculosis/  
National Center for Tuberculosis & Respiratory Infections, Inc.

## Network and Linkage (ACSM Activities)








Research Institute of Tuberculosis/  
National Center for Tuberculosis & Respiratory Infections, Inc.

Orientation of CHV in NTP Program



Basic DSSM Training for Lab Assistants





Research Institute of Tuberculosis/  
National Center for Tuberculosis & Respiratory Infections, Inc.

## Development of Recording Forms





Research Institute of Tuberculosis/  
National Center for Tuberculosis & Respiratory Infections, Inc.








- ### Operational Researches Conducted
- Effectiveness of Training Course on Quality Assurance of Chest Radiography
  - Health Care Seeking Behavior of Pulmonary TB Patients
  - Research on Tuberculosis Diagnostic Committee (TBDC)
- Research Institute of Tuberculosis/   
 National Center for Tuberculosis & Respiratory Infections, Inc.



- ### Accomplishment in the two project sites
- Engagement of NGOs (combined in both sites):
    - Number of NGOs from 3 (2008) to 5 (2010)
    - Number of NGO referring facilities: 4 (2008) to 15 (2012)
  - Percent contribution (combined in both sites) :
    - Percent contribution of NGO DOTS to TB Cases ranged from 27.9 % to 41.6 % (2007 to 2012)
    - Percent community contribution to TB Cases ranged from 2.1 % to 3.3 % (2010 to 2012).
- Research Institute of Tuberculosis/   
 National Center for Tuberculosis & Respiratory Infections, Inc.

**TECHNICAL ASSISTANCE SERVICES TO CAPACITATE  
COMMUNITY BASED ORGANIZATIONS (CBOs) AS RURAL  
HEALTH UNITS (RHUs) PARTNERS IN TUBERCULOSIS CONTROL**  
January 15, 2015 – April 30 2016

Funded by : Philippine Business for Social  
Progress/Innovations on Multi-Sectoral Partnership to  
Achieve Control of TB (**PBSP/IMPACT**)

**Criteria for Project site selection**

- Low TB performance ( LGU ) because of low utilization of DOTS services by the target clients
  - Low awareness of the TB disease
  - Stigma
  - Distance and cost in going to the facility
  - Lack of public involvement
- Strong political support
- Presence of CBOs

Research Institute of Tuberculosis/

**Project Goal**

- To increase the case detection rates and to improve or maintain Cure Rates in the six municipalities of Bulacan.


Research Institute of Tuberculosis/

**Roles of CBOs**

- Identify and refer presumptive TB to Rural Health Units (RHUs)
- Provide TB education
- Supervise TB treatment of patients


Research Institute of Tuberculosis/





## Roles of CBOs

- Encourage contacts of TB cases undergo TB screening at health centers
- Follow-up presumptive TB (who were not able to access RHUs) and interrupters of treatment



Research Institute of Tuberculosis/  
Tuberculosis Research Institute & Tuberculosis Research Center




## Challenges

- **Health financing:** reduce financial burden among clients
- **Health Resources for Health:** deployment of support systems and enabling environment; keep the motivation of Community Health Volunteers
- **Essential medical products and technologies:** Balanced diagnostic and treatment supplies




Research Institute of Tuberculosis/  
Tuberculosis Research Institute & Tuberculosis Research Center




## Contribution of CBOs to the 6 municipalities of Bulacan

| Municipalities | No. of TB All Forms |                    |                              |
|----------------|---------------------|--------------------|------------------------------|
|                | RHU Accomplishment  | CBO Accomplishment | % contribution by CBO to RHU |
|                | 1130                | 83                 | 7%                           |




Research Institute of Tuberculosis/  
Tuberculosis Research Institute & Tuberculosis Research Center




## Challenges

- Service delivery: Patient- centered approach care; improvement of access to quality TB services
- Lack of funding support to continue our community-based TB activities




Research Institute of Tuberculosis/  
Tuberculosis Research Institute & Tuberculosis Research Center




## Challenges

- **Leadership and Governance**
  - Continuity of adherence to policies (municipal ordinance) and make necessary amendments if needed;
  - Continuity of supportive supervision among NGOs.
- **Health Information system**
  - Utilization of data to inform policy change




Research Institute of Tuberculosis/  
Tuberculosis Research Institute & Tuberculosis Research Center




## Future Directions

- **TB and Universal Health Care**
- TB and Tobacco
- TB and Diabetes (?)
- Promote gender equality (?)



Research Institute of Tuberculosis/  
Tuberculosis Research Institute & Tuberculosis Research Center



Presentation and discussion of  
activities of partnership



Chang-Hua TB Care Association  
Taiwan

## Wei-Wen, Chen (Sally)

- \* **Griffith University, Queensland, Australia**  
Master of Gerontology Nursing **2003–2005**
- \* **Chang-Hua TB Care Association**  
Member **2014 –present**
- \* **Chang-Hua Hospital, Ministry of Health and Welfare, Changhua, Taiwan**  
Secretary and research assistant, MDR TB  
Department **2014 – present**

## Chang-Hua TB Care Association Taiwan

Presented by  
Wei-Wen Chen  
(Sally)




## Geographic Position



## Chih Yun, Lin (Vicky)


- \* **Fu Jen Catholic University, New Taipei City, Taiwan**  
Department of Life Sciences **2001–2005**
- \* **Chang-Hua TB Care Association**  
Supervisor **2012 –present**
- \* **Chang-Hua Hospital, Ministry of Health and Welfare, Chang-hua, Taiwan** **2008–present**

## Geographic Position



- Capital: Taipei
- The total area of Taiwan :36,193 km<sup>2</sup> (13,974 sq mi)
- Population: 23 million

## Geographic Position



## First meeting in 2009



## History

- \* The first non-governmental and non-profit making voluntary organization established in Chang-Hua County in March 2009 by **Dr. Yi-Wen Huang** (MD, Chief of Pulmonary and Critical Care Unit, Chang-Hua Hospital, Deputy commander of Central region communicable Disease Control Medical Network) with a view to raising public awareness against Tuberculosis (TB) and adopting preventive and curative measures towards the control of the diseases.



## Present Director 2015~

- \* Name: **Pei-Chun, Kuo**
- \* RN, Master of Health Care Administration, Central Taiwan University of Science and Technology
- \* Clinical Registered nurse since 1997
- \* Supervisor of Nursing Department, Chang-Hua Hospital since 2012~now



## The First Director 2009-2014

- \* Name: **Yi-Wen, Huang**
- \* MD, Kaohsiung Medical University 1975-1982
- \* Deputy commander of central region communicable medical network, CDC, Ministry and welfare since 2008~now
- \* Chief of Pulmonary and Critical Care Unit, Chang-Hua Hospital since 2010~now
- \* Chief of Emergency Department, Chang-Hua Hospital since 2008~now
- \* Chief of Tuberculosis Department, Chang-Hua Hospital since 2007~now
- \* Chief of Central Region MDR-TB team, since 2004~now



## Membership

- \* We pursue our mission in part through an open membership policy, any individual involved and interested in the objectives of the Association may apply for membership
- \* The Executive Committee shall decide as to the acceptance or not of any application and similarly decide into which category the applicant shall be placed.




## Membership

- \* For individuals: more than 20 years old and working in health care settings at Chang-Hua county or people living in Chang-Hua county
- \* For organizations: any associations or groups who agree objectives of the Association
- \* For sponsorships : people or groups who agree objectives of the Association



## TB epidemics in Taiwan TB Incidence by County, 1990-2013




## Membership

- \* 76 members
- \* Clinical staffs from hospital setting , community setting and DOTS.
- \* TB cases who completed treatments



## TB Case Number and Incidence, 2005-2013



The case number and age-adjusted incidence in 2013 declined with a rate of 30.0% and 43.4% compared with 2005.


17

## Aim/Purpose

- \* Support **disadvantage** and **special** groups to complete TB treatment thus reduce the chance to progress to MDR-TB
- \* We are a collaborative network of policy makers, health workers, researchers, people affected by TB and advocates.



## TB incidence rate in Chang-Hua 2009 -2014





## Mission

- \* Assist with **disadvantage** and **special** groups(eg. homeless, HIV, drug abused, psychiatrics, alcoholics, people living alone) who has suffering with TB (MDR & pre XDR TB) : improve their lives through financial support, education, and encouragement.




## Mission

- \* Fundraising for patients who is at low economical status or unqualified to retrieve governmental support, increase patients' motivations and adherence to complete treatment.
- \* The undertaking of the Research and Investigation on subjects concerning tuberculosis.
- \* Import & monitor new TB drug




## Mission

- \* Home visits by clinical staff or volunteers
- \* Strengthening clinical education for clinical TB staff



## Activities

- \* Regular medical allowance or food subsidies
- \* Provide toiletries for homeless cases



## Fundraising



## Challenges

- \* Chang-Hua county is mainly rely on urban agricultures
- Lack of TB information and knowledge
- Unable to recognized TB symptoms
- TB = Sin
- \* Delay hospitalization
- \* Short of funding





Presentation and discussion of  
activities of partnerships



TB/HIV Research Foundation  
Thailand



## Chiang Rai Province




In 1993 – HIV prevalence  
in military conscript was  
16.5% !



**TB/HIV RESEARCH FOUNDATION**  
(THRF SINCE 2002)  
LOCAL WISDOM... GLOBAL KNOWLEDGE

Registered Non-profit Non-government organization in Thailand # 222/2545  
<http://www.tbhivfoundation.org/index.php>

## TB/HIV in Chiang Rai province and NGO's responses



4

## PRESENTATION

1. About TB/HIV Research Foundation (THRF)
2. Highlight NGO's Role: The Volunteer Ladies Against TB

## THRF-HISTORY ( 1 )

- 1992, a group of Thai and Japanese doctoral students carried out their multi-disciplinary dissertation research on TB and HIV/AIDS (**THRF Founding members**)



- Epidemiology
- Clinical and public health
- Social sciences

## THRF-HISTORY ( 2 )

- **1995** The Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association (RIT/JATA) set up "TB/HIV Research Project"
- **2002** TB/HIV Research Foundation" (THRF) was officially registered as a non-profit, non-government organization



## PARTNERS



## THRF BOARD MEMBERS (NON-PAID)

- **President** Jintana Ngamvithayapong-Yanai, B.N. (Hons.), M.A., Ph.D.
- **Vice President** Pathom Sawanpanyalert, M.D. (Hons.), Dr.PH.  
Pacharee Kantipong, M.D.
- **Members** Petchawan Pungrassami, M.D., Ph.D.  
Supalert Nedsuwan, M.D., M.P.H.  
Surakameth Mahasirimongkol, M.D., M.Sc., Ph.D.  
Oranuch Nampaisan, B.Sc. (Statistic),  
M.Sc. (Biostatistics)
- **Treasurer** Piyanoot Chatchawarat, B. Econ., M.Ed. (Admin.)
- **Secretary** Sarmwai Luangjina, B.A.

**14 Fulltime paid staff**

## Funding Policy

- No funding from tobacco and alcohol related business
- Research with pharmaceutical company is a subject of board clearance
- Pharmaceutical company can donate money to charity (but NO company logo)



## Vision

Stop TB, HIV and other diseases of poverty, with the people for the people

## Mission

Involving and collaborating with local, national, international research and academic institutes, policy makers, NGOs, private sectors, civil societies and vulnerable populations (**with the people**) to reduce the burden on the people affected by tuberculosis, HIV/AIDS and other diseases of poverty (**for the people**) by means of epidemiology, bio-medical, social science, operational and participatory action research.

## WHAT WE DO ?



## Research and projects as of December 2015 ( 1 )

- Improvement of diagnosis by using urine test of detecting DNA fragment of *Mycobacterium tuberculosis* (RIT/JATA)
- Impact of isoniazid preventive therapy on TB morbidity and mortality: A cohort study of people living with HIV (JATA)
- Pharmacogenomic study of anti-tuberculosis side effects (MOPH/NIH and U.of Tokyo)
- Identification of blood transcriptional signature of active tuberculosis in Thai population (MOPH/NIH and U.of Tokyo)

## Charity

### Why research and charity?

- Most TB patients are poor
- Poverty cause treatment interruption and loss follow up
- Research staff are not rich!

## Research and projects as of December 2015 ( 2 )

- Ensuring treatment adherence through "CARE (Connection, Affordable, Reminder, and Enabling) Box" (Grand Challenge Canada)
- Evaluation of Rapid TB Culture and Drug Susceptibility Test through AutoMODS (Automated Microscopic Observation Drug Susceptibility) (Global Fund and National Innovation Association)
- Interventions for reducing sodium intake among patients with hypertension (Thailand Health Promotion Foundation)
- Workshops on TB in risk groups (JATA-seal funding)

We were very sick and we could not go to work. We feel so bad that our son (13 years) left the school and earned income by boxing and labor work. We do not have money to go to the hospital. Firstly, we must have foods to feed the whole family.



Photo and story credit: Sarmwai Luangjina - 2009


## Human resource development and technical collaborations

- Training for community volunteers and prisoner volunteers about TB
- Member, Global Fund Thailand Country Coordinating Mechanism CCM
- Member, TB Laboratory Expert Committee, MOPH
- Technical collaboration with local NGOs, NTP/MOPH and National Health Insurance
- Field practicum in **statistics and global health** for students from universities in Thailand and School of Public Health University of Alberta, Canada

## Charity

- **2007:** established a TB patient-fund (Center for Sharing) to support very poor TB patients for transportation and living expenses. (initial 3,000 US\$ fund from StopTB Partnership, Geneva)
- **2009:** THRF and JATA established Volunteer Ladies Against TB to sustain the patient-fund and to support TB care





## Who are Volunteer Ladies Against TB?

- majority are Chiang Rai origins, age > 60 yrs, good socioeconomic status
- active in several volunteer activities not only TB activities



## CHALLENGES

- Recruiting and maintaining qualified medical research and admin staff with good English command in Chiang Rai
- Limited international research funding due to being "high middle income country"
- Sustaining charity activities without budget for staff running charity activities

## How did we engage Volunteer Ladies?

- Listed the existing women organizations in Chiang Rai
- Invited to the first workshop and 2 follow up workshops
- Built TB awareness by presenting TB epidemiology data
- Inspired and motivated by sharing experiences from **Japanese Women Association**



## PRESENTATION

1. Overview about TB/HIV Research Foundation (THRF)
2. Highlight NGO's Role: The Volunteer Ladies Against TB



The Chiang Rai Ladies  
Volunteers Against TB  
*"Eradicating TB with women's  
hands and heart"*

1. Fund raising for "Center for Sharing"
2. Packing daily TB drugs to ease medication
3. Visit to patients' home - supporting foods and sharing psychological support



## How Volunteer Ladies support TB patients? (data as of Dec. 2015)

### 1. Fund raising to support TB patient funding

- Funding increased from 3,000 US\$ in 2009 to 28,040 US\$ in 2015
- Total 487 patients received financial support to enhance treatment completion (279 Thai, 165 hilltribe minorities, 43 Myanmar migrants)



I was very sick and thought that I was going to die. Thanks to the volunteers bringing me back to the hospital and complete TB treatment. After my TB was cured, I was pregnant and delivered a baby. I am so happy



### 2. Assisting the hospital's pharmacists in packing daily dosage of anti-TB medicine to make the medication regime easier to follow for patients



**77,403 packs were packed!**



Photo and story credit: Chayut Kaewsitdhi and Sarmwai Luangjina 2010



### 3. Home visits to the extremely poor patients and patients encountering stigma and social isolation

- 90 patients were visited (67 Thai, 12 hilltribe minorities, 11 Myanmar migrants)
- All completed treatment except 3 died (TB/HIV) but died with human touch
- Reduce stigma, tears of smile



## NEXT STEP

Research to enhance “**Bold Policy**”

- How social protection interventions help **Ending TB** and contribute to social and economic development?
- Can women’s hands and hearts help **Ending TB**



## Appendix 5

**Group Discussion 1:** 15 March 2016 (10:15 – 11:45)

**Topic:** Challenges of NGO to End TB and role of women

**Moderator:** Nobukatsu Ishikawa

**Rapporteur:** Jintana Ngamvithayapong-Yanai

The moderator started the discussion by showing a list of roles of NGOs/CSOs to cover for End TB, as following:

- hard to reach groups/poor patients
- care/support to catastrophic cost
- Social protection (e.g., Stigma, discrimination)
- Universal health coverage (UHC)
- Use of community health volunteers
- Engage TB and Non-TB sectors
- Social linkage
- local authorities
- Advocacy voice for the voiceless
- Community empowerment
- Communicate/coordinate stakeholder
- Conducting research

The moderator then requested each NGO to write a top three challenges in three pieces of post-it note paper. One piece for one challenge which they think are challenges for NGO to End TB. All NGOs posted their lists on a big board. Later, the moderator created categories based on the lists presented in the Table 1. Table 2 presents challenges classified by NGO/country as discussed in the country presentations and in the document for End TB.

**Table 1:** The top-three free listing of perceived challenges to NGOs/CSOs to end TB

| Categories of Challenges (Number)                     | List of challenge (country)   |
|---|---|
| Challenges related to community health volunteers (5) | <ul style="list-style-type: none"><li>- How to maintain and keep volunteers actives?<br/>(Indonesia, Thailand)</li><li>- Need of resource and incentives for volunteers (Indonesia, Myanmar, Philippines)</li></ul> |



|   |   |
|---|---|
|   | <ul style="list-style-type: none"> <li>- Case findings still low in remote area and volunteers can do more (Cambodia)</li> </ul>  |
| Challenges related to funding (4)                                   | <ul style="list-style-type: none"> <li>- Budget sustainability (Korea)</li> <li>- Limited resources, funding (Cambodia, Nepal, Philippines)</li> </ul>  |
| Challenges related to support to TB patients and poor patients (4)  | <ul style="list-style-type: none"> <li>- Addressing inequality in TB patient (Philippines)</li> <li>- Advocacy voice for vulnerable people (Thailand)</li> <li>- Need of nutrition support to patients (Myanmar)</li> <li>- Patient confidentiality (Taiwan)</li> </ul> |
| Challenges related to patients and community awareness about TB (3) | <ul style="list-style-type: none"> <li>- Need to increase TB awareness among community people (Taiwan, Thailand, Myanmar)</li> </ul>  |
| Challenges related to stakeholders (3)                              | <ul style="list-style-type: none"> <li>- Lack of consensus between government and NGO (Korea)</li> <li>- Satisfaction for donors or satisfaction of patients? (Korea)</li> <li>- High expectations from stakeholders (Nepal)</li> </ul>                                 |
| Challenges related to professional care providers (2)               | <ul style="list-style-type: none"> <li>- Difficulty in implementing International Standard of TB care among the providers (Indonesia)</li> <li>- Less capacity in conducting research and development (Nepal)</li> </ul>  |
| Other (1)   | <ul style="list-style-type: none"> <li>- Migration (Cambodia)</li> </ul>  |

**Table 2:** Challenges of NGO to End TB classified by country

| Organization, Country             | Challenges of NGO to End TB   |
|-----------------------------------|---|
| Stop TB Partnership, Korea        | <ul style="list-style-type: none"> <li>- Budget sustainability</li> <li>- Lack of consensus between government and NGO</li> <li>- Satisfaction for donors or satisfaction of patients?</li> </ul> |
| Chang-Hua Hospital / TATA, Taiwan | <ul style="list-style-type: none"> <li>- Awareness of TB among community and society</li> <li>- Stigma and discrimination</li> <li>- Confidentiality of patient side, Privacy</li> </ul>          |

|                                  |   |
|----------------------------------|---|
| Stop TB Partnership<br>Indonesia | <ul style="list-style-type: none"> <li>- Difficulty keeping the volunteers active</li> <li>- Need resources to support the volunteers</li> <li>- Difficulty implementing International Standard of TB care among the providers</li> </ul>   |
| THRF, Thailand                   | <ul style="list-style-type: none"> <li>- TB awareness among general people</li> <li>- Advocacy voice for vulnerable people</li> <li>- Sustainability of volunteers</li> </ul>   |
| JANTRA, Nepal                    | <ul style="list-style-type: none"> <li>- Limited resources</li> <li>- Less capacity in research and development</li> <li>- High expectations from stakeholders</li> </ul>   |
| CATA, Cambodia                   | <ul style="list-style-type: none"> <li>- Limited fund</li> <li>- Case finding is still low</li> <li>- migration</li> </ul>  |
| MMWA, Myanmar                    | <ul style="list-style-type: none"> <li>- To increase community awareness by providing more IE&amp;C materials and community health talk</li> <li>- Funding for nutrition and transportation support for patients</li> <li>- Volunteer incentive is not enough for the targeted 330 townships for providing psycho-social support to complete treatment</li> </ul> |
| RIT/JATA, Philippines            | <ul style="list-style-type: none"> <li>- Provision of incentive</li> <li>- Funding support</li> <li>- Addressing patients' inequality</li> </ul>  |

The challenges related to “funding” was not included in this discussion session because the afternoon session will specifically discussed about fundraising. The group members shared their experiences and participated in discussion of the following issues:

#### 1. Challenges related to community health volunteers

Turnover rate of the volunteers is common in most countries because of lack of incentives, lack of recognitions by community people, particularly recognition from people with high social and economic status. The following strategies may motivate volunteers to stay longer and increase volunteers' dignity or recognitions:

##### 1.1 Provision of incentives including

- special right to access free health service,
- organize periodic meetings and let the volunteer to report their performance
- organize “exchange visit” so that the volunteers open their eyes to expose to other

sites

- organize training to increase TB knowledge
- provide transportation fee, award ceremony for outstanding volunteers

1.2 To enhance dignity, the volunteers should be selected by community people

Despite provision of these incentives and motivation, several participants felt the turnover rate of the volunteer is still high and require additional interventions. JUNTRA Nepal proposed “Trust fund” as an intervention motivating volunteers to actively work with dignity.

## 2. Enhancing TB awareness

Participants shared their opinion on enhancing TB awareness as followings:

- Means and message to convey TB information to people living in remote area should be cultural sensitive.
- TB patients and their family should be involved in providing TB education to the community
- It is important to repeat TB education to every level
- Enhancing the role of peer group (TB patients group)

The moderator concluded summarizing the sessions that the roles and challenges of NGOs/CSOs are diverse and varies according to the country and organization, but key common issues such as community and patient oriented approach were discussed and shared, and this kind of sharing is a most useful to promote the spirit of stop TB partnership. For that, documentation of the success stories is important. A term of human dignity was raised particularly for community health volunteers' motivation, but the concept could apply to all aspect of the work by NGOs/CSOs.

**Session 2:** 15 March 2016 (13:00 – 14:30)

**Topic:** Fundraising for the community activities

**Moderator:** Jintana Ngamvithayapong-Yanai

**Rapporteur:** Ram Sharan Gopali

The moderator started the session by showing a short video clip on “Japan hosts ‘Touch-a-boob’ fundraising event” <https://www.youtube.com/watch?v=pUi-FlfzHlw>. This is the second most viewed video clip in the YouTube for a searching keyword of “fundraising”. The video shows how Japanese Foundation for AIDS Prevention (a Japanese NGO) raised US\$50,000 within 24 hours with the objectives to raise HIV awareness in Japan and raise fund to support HIV prevention, treatment and care. Several Japanese porn queens voluntarily contributed to this fund raising. The participants discussed how they felt and whether or not this fundraising methodology can be applied in their countries. All participants reported this fundraising method cannot be applied because it is against law and culture in their respective countries.

Following this introductory video, the moderator presented topics for the discussion. All participants agreed with the topics. Results from the discussion are summarized as follows: Current community TB activities requiring fund include:

1. Activities directly related to patient supports include; supporting patients’ transportation, providing foods to complete TB treatment, and home visit
2. Activities related to community volunteers include; support for meetings, training and allowance for volunteers
3. International community TB activities

**Table 1:** Current funding sources of the participants’ NGOs

| Organization, Country             | Funding sources   |
|-----------------------------------|---|
| Stop TB Partnership, Korea        | The operational cost is funded by the government of Korea and programmatic budgets are from several funding sources such as Koica, Korean Anti-TB Association |
| Chang-Hua Hospital / TATA, Taiwan | For TATA, 80% of funding are from the president, Christmas seal. As for Chang Hua, funding are from membership, donation of members, pharmaceutical companies |
| Stop TB Partnership               | Entire fund is from the Chairperson (owner of oil company)  |

|                       |  |
|-----------------------|--|
| Indonesia             |  |
| THRF, Thailand        | Research funding for research activities For charity, mostly come from the volunteer ladies' fundraising   |
| JANTRA, Nepal         | For regular funding is from RIT/JATA. For project implementations are from Global Fund, Stop TB partnership, TBREACH                                   |
| CATA, Cambodia        | JATA, USAID, TBREACH   |
| MMWA, Myanmar         | For regular fund are from membership fee, properties (renting lands/building), running pre-school. For project are from several sources such as UNICEF |
| RIT/JATA, Philippines | JATA, MOFA, JICA, USAID  |

Participants learnt that MMWA has 12 million members and each member pay about 0.2 US\$ for life-long membership and they receive a pin and a certificate to be a member.

**Table 2:** Fund raising methods of NGOs participating in the meeting

| Organization, Country             | Methods of fund raising  |
|-----------------------------------|--|
| Stop TB Partnership, Korea        | <ul style="list-style-type: none"> <li>- Developing proposal for funding</li> <li>- Putting donation box in department store, post office and bank (obtained very small amount)</li> </ul>                                     |
| Chang-Hua Hospital / TATA, Taiwan | <ul style="list-style-type: none"> <li>- Annual donation by people (Taiwanese people like donation)</li> <li>- Donation from pharmaceutical companies (cash and medicine) -selling Christmas seals</li> </ul>                  |
| Stop TB Partnership Indonesia     | <ul style="list-style-type: none"> <li>- Organizing charity events such as cultural night, sport competition to high income people</li> </ul>  |
| THRF, Thailand                    | <ul style="list-style-type: none"> <li>- Developing proposal for research funding</li> <li>- For charity: The volunteer ladies raise the fund by self-donation, organizing gala dinner, donation from other sources</li> </ul> |
| JANTRA, Nepal                     | <ul style="list-style-type: none"> <li>- Developing proposal for funding</li> </ul>  |
| CATA, Cambodia                    | <ul style="list-style-type: none"> <li>- Organizing field visit for Japan Women Anti-TB Association</li> <li>- Developing proposal for funding</li> </ul>  |
| MMWA, Myanmar                     | <ul style="list-style-type: none"> <li>- Donation from donors</li> <li>- Selling calendar and magazine</li> </ul>  |
| RIT/JATA, Philippines             | <ul style="list-style-type: none"> <li>- Developing proposal for funding</li> </ul>  |

### **Funding from tobacco, alcohol and pharmaceutical companies**

All participants recognized tobacco and alcohol as risk factors for TB. Therefore, their organizations do not accept funding from tobacco and alcohol related business. Particularly, Stop TB partnership Indonesia's mission also includes stop tobacco. Cambodia implemented TB prevention project in tobacco factory but does not receive funding from the company. As for funding from pharmaceutical companies, participants from Korea, Taiwan and Thailand reported that they accepted donation with conditions. For examples, the pharmaceutical companies can donate money to support TB activities as if they are an individual donor. Therefore, the company's logo must not appear in the product or the events funded by the pharmaceutical companies. JUNTRA, CATA and RIT/JATA Philippines have never been approached by pharmaceutical company. In addition to pharmaceutical business, Myanmar MMWA also reject funding from some baby products such as baby talcum, milk or baby food. The senior participants from RIT shared the information that pharmaceutical companies are also members of Stop TB Partnership Japan. Accepting funding from this business sector should be considered based on the conditions and context of funding proposal.

The moderator closed the session by concluding that funding is important for running NGO and implementing community activities. The discussion shows that integrity to accept or to raise funding is priority for all participants.





## Tokyo Statement on Community Engagement in End TB Strategy *Asian National Stop TB Partnership Forum 2016*

The Asian National Stop TB Partnership Forum 2016 was held on March 14-15, in Tokyo, Japan, with the participation of a total of 18 delegates from 8 Asian countries / territories (Cambodia, Indonesia, Korea, Myanmar, Nepal, Philippines, Taiwan, and Thailand). These participants represented the non-governmental organizations (NGO) and other civil society organizations (CSO) engaged in tuberculosis control.

The missions of the Forum were;

- To enhance people's awareness of the importance of their ownership for and commitment to tuberculosis control activities,
- To promote the effective collaboration between governmental and non-governmental sectors in the fight against tuberculosis, with special reference to the potentiality of women's roles,
- To clarify the problems and challenges of tuberculosis control of each target area or community to be addressed in their action plans, and
- To advance cooperation between partners of different groups beyond country borders.

During the two-day meeting the participants shared their experiences and views of their groups, as well as those of the Women's anti-TB Association and Western Pacific Region of WHO, and had discussions over the ways to enhance respective groups' activities in the perspective of End TB Strategy. Following are the summary findings of presentations, discussions, and proposals from the forum, as agreed upon by all the participants.

### Background: Paradigm shift in the fight against tuberculosis

Along with the paradigm shift from the Millennium Development Goals to Sustainable Development Goals, the global TB program has turned to End TB Strategy as endorsed in 2014. In this strategy, tuberculosis is recognized more clearly than ever as a socio-economic challenge, not merely as a medical issue, to which more engagement of communities, or non-governmental organizations, is badly needed, as claimed throughout the pillars of the strategy. Specifically, integrated, patient-centered TB care and

prevention is claimed as the fundamental element in Pillar 1. This is also stressed in the Regional Framework developed by WPRO, adapting the End TB Strategy to its regions.

### **Roles of NGOs in End TB Strategies: Missions, Opportunities, and Challenges**

In country presentations and group discussions, the following four points were highlighted as important roles of NGOs / CSOs, each with special emphasis as supplemented in numbers 1, 2, .... Although the roles and challenges of NGOs/CSOs are diverse and variable according to the countries and organizations, the key issues such as community and patient-oriented approach were common, and this sharing was felt as most critical in promoting the spirit of the stop TB partnership.

#### *1) Cooperation with the government in implementing NTP*

1. Supporting TB case detection through urging symptomatic subjects, or TB suspects, to visit health facilities.
2. Encouraging patients to take medications regularly.
3. Increasing the awareness and knowledge of TB among community people on various occasions to reduce the stigma, discrimination and superstition, and to take proper action against illnesses.

#### *2) Social support of patients and families*

1. Supporting, educating, and empowering patients and their family facing financial barriers through forging UHC.
2. Providing patients with food, transport, housing, etc., as important areas of patient support.

#### *3) Advocacy*

1. Advocating voices of patients and vulnerable people.
2. Increasing awareness of TB among the community.
3. Creating patients' groups, so that they have a stronger voice for claiming better service and protection, and also enhancing community awareness of TB.
4. Creating peer support groups with high capacity to support vulnerable groups (e.g., the very poor, women, children, HIV-infected or elderly persons, etc.).
5. Advocating research for TB control, especially operational researches

and researches involving community activities.

6. Engage other areas of the society/community with TB, such as education, agriculture and MCH, etc..
7. Empower health activists and volunteers to set up networks at grass-root level involving other community members

#### *4) Women's roles and potentials*

1. Gender equity should be addressed in TB care, including access to health services and knowledge of TB.
2. Women's potential in community activities should be fully recognized.

#### **Fund raising issues**

Many groups suffer from inadequate budgets, but few of them use specific schemes of their own for fund raising, e.g., Christmas-seal campaign, Calendar sales, donation box (in shops, etc.), and charity events, in addition to donations from individuals (group members and others) and companies.

Other funding sources include government programs, the Global Fund, WHO, Union, Stop TB Partnership, UNICEF, other bilateral plans (e.g., JATA, USAID, TBREACH), and charitable foundations.

Apart from the inadequacy of funds, possible concern may exist for receiving donations from pharmaceutical industries (in some countries, also other health-related businesses), to say nothing of donations from tobacco and alcohol industries.

#### **Challenges**

1. The high turn-over rate of volunteers is common, possibly due to inadequate incentives and lack of community recognition, or volunteers' dignity.
2. Incentives for volunteers may include privileged free access to health services, periodic meetings for reporting volunteers' activities, opportunities of training and exchange with other groups, awarding for outstanding performance, and provision of travel allowances.
3. Addressing patient's confidentiality or privacy.
4. In some cases, consensus between government and NGOs is not enough, and some care providers have difficulty in implementing International Standards of TB Care.
5. Low capacity of research activities, when NGO's operational research is

expected as very significant, especially in UHC and social protection schemes.

6. Documentation of success stories of community activities may be important in sharing recognition of bases of TB control such as UHC and patient-centered care.

### Forum slogan

The forum decided to adopt a following slogan to be shared by member organizations as a priority message of activities.

- *Women are creators of community health through family health.*

### Acknowledgement

The Forum acknowledges the contribution and efforts of the following individuals and organizations that made the meeting possible and successful. The Forum also expresses deep thanks to the observers for their kind interest in the meeting.

### Participants

[Organization] Cambodia: National Center for TB and Leprosy control (CENAT), Cambodia Anti-Tuberculosis Association (CATA). Indonesia: Headquarters of Forum Stop TB Partnership Indonesia and Stop TB Partnership Cimahi City, Korea: Korean National Tuberculosis Association (KNTA), Stop TB Partnership Korea, Myanmar: Myanmar Maternal Welfare Association (MMWA), National Tuberculosis Program, Kachin State, Nepal: Japan-Nepal Health & TB Research Association (JANTRA), Philippines: RIT/JATA, Philippines Inc. (RJPI), Taiwan: Taiwan Anti-TB Association (TATA), National Chang-Hua Hospital MDR TB Department, Thailand: TB/HIV Research Foundation (THRF), Chiang Rai Volunteer Ladies against TB

[Member] Cambodia: Khloeung Phally, Monyrath Chry, Chharvy Ringsey Keo, Indonesia: Mariani Reksoprodjo, Fitriani Manan, Korea: Seungjoon Chang, Kanghee Kim, Hong Jo Choi, Myanmar: Tha Zin Nwe, Ei Ei Chaw, Nepal: Ram Sharan Gopali, Jamuna Panthi, Philippines: Aurora G Querri, Leonardo G. Parungo Jr, Taiwan: Chih-Yun Lin, Wei-Wen Chen, Thailand: Sarmwai Luangjina, Jintana Ngamvitayapong-Yanai

### Staff

[Organization] Stop TB Partnership Japan, Japan Anti-Tuberculosis Association (JATA), Research Institute of Tuberculosis, JATA, Council of Japanese Women's Anti-Tuberculosis Associations, Western Pacific Regional Office of World Health Organization

[Member] Ram Sharan Gopali, Makiko Goto, Yumi Ishikane, Nobukatsu Ishikawa, Shoji Kudo, Ayako Miyamoto, Toru Mori, Nobuyuki Nishikiori, Jintana Ngamvitayapong-Yanai Kosuke Okada, Kintaro Shibuya, Noriko Shirasu, Noriyo Shimoya, Keiji Tanaka, Tomoko Tsuji, Takeko Yamashita





## アジア・ナショナル・ストップ結核パートナーシップフォーラム 2016

---

日 程：2016 年 3 月 14 日・15 日

場 所：国連大学、結核予防会結核研究所

主 催：認定特定非営利活動法人ストップ結核パートナーシップ日本

協 賛：公益社団法人全国結核予防婦人団体連絡協議会

協 力：公益財団法人結核予防会



## 報 告

### アジア・ナショナル・ストップ結核パートナーシップフォーラム 2016

アジア・ナショナル・ストップ結核パートナーシップフォーラム 2016 は、2016 年 3 月 14、15 日東京で開催された。下記は、フォーラムにおける発表、討論の総括である。

#### メインテーマ

アジアの「結核早期根絶戦略」における住民の役割

#### 会議の目的

アジアの各国・地域のストップ結核パートナーシップ（ないし相当組織、例. 結核予防会）が一堂に会して、それぞれの国・地域におけるより早期の結核根絶達成のための、住民による（非政府組織としての）現在の活動、今後の計画、およびそれらを強化する可能性、加えて各国・地域の間の協力や連携について討議する。アジアの「結核早期根絶戦略」の早期目標達成に向けて、特に、女性の役割、国境を越えたパートナーシップ間の連携の可能性に重きを置く。

#### 期待される成果

1. 結核対策への住民の主体的な取り組みの重要性に対する自覚を強化する
2. 結核予防・ケアにおける政府と民間セクターの効果的な協力を向上させる
3. 参加国・地域の状況の比較に基づく、それぞれ特有の問題点、優先課題を明らかにし、それらに対する民間セクターとしての対策行動計画案を作成する
4. 住民活動における女性の取り組みの可能性への理解を深める
5. 各国・地域のパートナーシップ間の協力や連携を強化する

#### 日 程

2016 年 3 月 14 日、15 日

#### 会 場

国連大学 東京都 渋谷区（3 月 14 日）

（公財）結核予防会 結核研究所 東京都 清瀬市（3 月 15 日）

#### 参加者

8 ヶ国/地域の非政府組織を代表する 18 人が招待された（付録 1 を参照）。

加えて、外務省、JICA を含む様々な政府、非政府組織、グループから 26 人のオブザーバが出席した。

## 会議内容と成果

1. 開会挨拶と参加者、スタッフの紹介： 3月14日（国連大学）  
座長： 森 亨（ストップ結核パートナーシップ日本 代表理事）
2. 基調講演1： 3月14日（国連大学）  
テーマ： 日本における結核予防婦人団体の活動  
講師： 山下武子（結核予防婦人団体協議会 事務局長）  
概要：付録 2 を参照
3. 基調講演2： 3月14日（国連大学）  
テーマ： アジアにおける今日の結核問題の課題  
講師： 錦織信幸（世界保健機関（WHO）西太平洋地域事務局ストップ結核・ハンセン病対策調整官）  
概要：付録 3 を参照
4. 結核予防婦人団体協議会表敬訪問・交流：  
3月14日（結核予防婦人団体協議会総会 会場 ホテル・ニューオータニ ）
5. 各参加国・地域の活動の発表： 3月14日、15日（結核研究所）  
座長： 岡田耕輔（結核予防会国際部 部長）  
概要：付録 4 を参照
6. グループ討議1： 3月15日（結核研究所）  
テーマ： 民間結核対策活動の課題と女性の役割  
モデレーター： 石川信克（結核予防会 結核研究所 所長）  
概要：付録 5 を参照
7. グループ討議2： 3月15日（結核研究所）  
テーマ： 住民活動の資金造成の計画作成  
モデレーター： ジンタナ・ヤナイ（タイ結核-HIV 研究財団）  
概要：付録 6 を参照
8. フォーラム宣言文の採択： 3月15日（結核研究所）  
座長： 森 亨（ストップ結核パートナーシップ日本 代表理事）  
概要：付録 7；東京宣言 アジア・ナショナル ストップ結核パートナーシップフォーラム 2016  
を参照
9. 懇親会：3月15日（結核研究所）  
特別ゲスト： 渋谷金太郎（清瀬市 市長）

東京宣言 「結核早期根絶戦略」におけるコミュニティの参加  
アジア・ナショナル・ストップ結核パートナーシップフォーラム 2016

アジア・ナショナル・ストップ結核パートナーシップフォーラム 2016 は、アジアの国・地域（カンボジア、インドネシア、韓国、ミャンマー、ネパール、フィリピン、台湾、タイ）を代表する合計 18 名の参加により、3 月 14～15 日に東京で開催された。参加者は、結核対策に関わる NGO、CSO を代表する。

フォーラムのミッション；

1. 結核対策における住民の主体的な取り組みの重要性に対する自覚を強化する
2. 特に女性の役割の可能性に関連した結核予防・ケアにおける政府と民間セクターの効果的な協力を促進する
3. 参加国・地域の状況の比較に基づく、それぞれ特有の問題点、優先課題を明らかにし、それらに対する民間セクターとしての対策行動計画案を作成する
4. 各国・地域のパートナーシップ間の協力や連携を強化する

2 日間の会議の中で、参加者たちは、結核予防婦人団体協議会や WHO 西太平洋地域事務局（WPRO）、そして各グループの経験や視点を共有し、「結核早期根絶戦略」の見地に立ち、それぞれの活動強化について話し合った。下記は、参加者全員の合意によるフォーラムでの発表、討論の総括と提言である。

**背景：結核終息へ向けた戦いの枠組みの転換（パラダイムシフト）**

「ミレニアム開発目標」から「持続可能な開発目標」へのパラダイムシフトに伴い、WHO のグローバル結核対策計画も 2014 年に承認された「結核終息戦略」へ移行した。この戦略において、結核は単なる医学的な問題としてではなく、明確に社会経済的な課題と認識され、住民や非政府組織による取り組みが戦略の柱として今まで以上に重要視されている。特に、統合された患者中心の結核治療（ケア）と予防は、第 1 の柱の基本的な要素である。これは、「結核終息戦略」を地域別に適合させた WHO 西太平洋地域事務局（WPRO）による「地域フレームワーク」においても強調されている。

**「結核終息戦略」における NGO の役割：ミッション、機会、課題**

国ごとの発表、グループ討議の中で、NGO、CSO の重要な役割として以下の 4 つの点と其中で特に強調すべき点がそれぞれ補足 1. 2…として挙げられた。それぞれの NGO、CSO の役割や課題は、国や組織によって多種多様であるが、住民と患者中心のアプローチなどの重要な論点は共通であり、このことはストップ結核パートナーシップのスピリットを促進するのに最も重要と感じられた。

**1) 国の結核対策計画（NTP）の現場における政府との協力**

1. 結核の疑い患者や有症状患者を医療施設への受診をの促進して結核の早期発見を支援する。
2. 患者の定期的な服薬を働きかける。
3. 地域住民の結核に対する知識や認識を向上させ、偏見、差別、迷信をなくし、病気に対して適切な



行動がとれるようにする。

## 2) 患者と家族に対しての社会的な支援

1. 経済的困難に直面する患者やその家族に対して、全国民医療サービス（UHC）推進を通して患者を支援し、教育し、エンパワーする。
2. 患者支援の重要な要素として、患者に食物、交通手段、住居を供給する。

## 3) アドボカシー

1. 患者や弱者の声を代弁する。
2. 地域社会での結核への認識を向上させる。
3. 社会保障やサービスについて要求し、それによって地域社会の結核に対する意識を高める声を大きくするために、患者団体をつくる。
4. 弱者（貧困者、女性、子供、HIV感染者、高齢者など）を支援するピアサポートグループ（相互支援グループ）をつくる。
5. 結核対策に係る調査、特にオペレーショナル・リサーチや住民活動を含む調査を提唱する。
6. 教育や農業、母子保健など結核とは異なる領域と連携する。
7. 結核領域以外の住民を巻き込み、草の根レベルのネットワークをつくるべく、健康問題関連の活動家とボランティアの能力を高める。

## 4) 女性の役割と可能性

1. 保健サービスの利用や結核の知識を含め、結核のケアにおいても両性の平等について強調されるべきである。
2. 住民活動における女性の可能性を十分に認識するべきである。

## 資金造成

多くのグループで予算は不十分であるが、いくつかのグループでは、独自の方法で資金造成をしている。個人（グループのメンバーやその他）や企業からの寄付に加え、例えば、クリスマスシルキャンペン、カレンダー販売、募金箱（店頭で）、チャリティーイベントなどがあげられる。

政府のプログラムを含め、グローバルファンド、WHO、国際結核肺疾患予防連合、ストップ結核パートナーシップ、また二国間援助（JATA、USAID、TBREACH）や寄付財団などがその他の資金造成としてあげられる。

資金不足の見地から離れるが、タバコやアルコール産業からの寄付は言うまでもなく、製薬企業（国によっては、健康関連ビジネスも）からの寄付についての懸念も存在している。

## 課 題

1. おそらく不十分なインセンティブや地域社会での認識不足、尊厳の認識不足によるボランティアの離任率の高さは共通である。
2. ボランティアへのインセンティブは、保健サービスの無償化、ボランティアの活動報告の定例会議

やトレーニング、他のグループとの意見交換の機会の提供、優秀な活躍に対する褒賞の授与や交通費の提供も含まれる。

3. 患者の機密保持やプライバシーについて重視する。
4. 政府と NGO 間の共通認識が十分ではないことがある。いくつかの結核ケア提供者は、「結核ケアの国際標準」によるサービスを提供する事が困難である。
5. NGO によるオペレーショナル・リサーチ特に UHC や社会的保護についての研究が重要とされるに関わらず、NGO の研究実施能力が低い。
6. UHC と患者中心のケアなど、結核対策の基本認識を共有するために、住民活動の成功事例を文書化することは重要と思われる。

## フォーラムスローガン

活動の優先メッセージとして、参加者によって下記のスローガンが採択された。

- 女性はコミュニティの健康の創造者

## 謝 意

このフォーラムの開催を可能にし、成功に導いてくださった下記の個人や組織にお礼を申し上げます。またフォーラムはこの会議に興味を持ってくださったオブザーバの方に深い感謝を示します。

## 参加者

[Organization] Cambodia: National Center for TB and Leprosy control (CENAT), Cambodia Anti-Tuberculosis Association (CATA). Indonesia: Headquarters of Forum Stop TB Partnership Indonesia and Stop TB Partnership Cimahi City, Korea: Korean National Tuberculosis Association (KNTA), Stop TB Partnership Korea, Myanmar: Myanmar Maternal Welfare Association (MMWA), National Tuberculosis Program, Kachin State, Nepal: Japan-Nepal Health & TB Research Association (JANTRA), Philippines: RIT/JATA, Philippines Inc. (RJPI), Taiwan: Taiwan Anti-TB Association (TATA), National Chang-Hua Hospital MDR TB Department, Thailand: TB/HIV Research Foundation (THRF), Chiang Rai Volunteer Ladies against TB

[Member] Cambodia: Khloeung Phally, Monyrath Chry, Chharvy Ringsey Keo, Indonesia: Mariani Reksoprodjo, Fitriani Manan, Korea: Seungjoon Chang, Kanghee Kim, Hong Jo Choi, Myanmar: Tha Zin Nwe, Ei Ei Chaw, Nepal: Ram Sharan Gopali, Jamuna Panthi, Philippines: Aurora G Querri, Leonardo G. Parungo Jr, Taiwan: Chih-Yun Lin, Wei-Wen Chen, Thailand: Sarmwai Luangjina, Jintana Ngamvitayapong-Yanai

## スタッフ

[Organization] Stop TB Partnership Japan, Japan Anti-Tuberculosis Association (JATA), Research Institute of Tuberculosis, JATA, Council of Japanese Women's Anti-Tuberculosis Associations, Western Pacific Regional Office of World Health Organization

[Member] Ram Sharan Gopali, Makiko Goto, Yumi Ishikane, Nobukatsu Ishikawa, Shoji Kudo, Ayako Miyamoto, Toru Mori, Nobuyuki Nishikiori, Jintana Ngamvitayapong-Yanai Kosuke Okada, Kintaro Shibuya, Noriko Shirasu, Noriyo Shimoya, Keiji Tanaka, Tomoko Tsuji, Takeko Yamashita



## Asian National Stop TB Partnership Forum 2016

Date : 14-15, March, 2016

Venue 1 : 1F HALL United Nations University,

Venue 2 : Hotel New Otani

Venue 3 : Research Institute of Tuberculosis (RIT)





































## The Asian National Stop TB Partnership Forum 2016

---

Date: November, 2016  
Published by: Stop TB Partnership Japan  
Kekkaku-Yobokai, Misaki-sho 1-3-12,  
Chiyoda-ku, Tokyo 101-0061 Japan  
Tel 03-5282-3010 Fax 03-5980-8267  
www.stoptb.jp  
Funded by: Japanese Council of Women's Anti-TB Associations

## アジア・ナショナル・ストップ結核パートナーシップフォーラム 2016

---

発行: 2016 年 11 月  
発行者: 認定特定非営利活動法人 ストップ結核パートナーシップ日本  
〒101-0061 東京都千代田区三崎町 1-3-12 結核予防会内  
Tel 03-5282-3010 Fax 03-5980-8267  
www.stoptb.jp  
協賛: 公益社団法人 全国結核予防婦人団体連絡協議会

